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CHAPTER 1. INTRODUCTION
1.1 Human kinome and protein kinase domain
1.1.1 Protein kinases
Protein kinases are the enzymes that catalyze protein phosphorylation, one
of the most important protein post-translational modifications (PTMs), by
transferring a phosphate group from the nucleotide molecules (e.g., Adenosine
triphosphate (ATP)) to the substrate proteins (Fontana & Lovenberg, 1973;
Guidotti, Kurosawa, Chuang, & Costa, 1975; Insel, Bourne, Coffino, & Tomkins,
1975). Protein phosphorylation is critical to activate or deactivate protein functions:
by adding a phosphate group, the protein conformation is altered, subsequently,
the protein switches to “on” or “off” states that may enhance or reduce downstream
cell signaling (Burnett & Kennedy, 1954; Cohen, 1982; O'Connor, Gard, &
Lazarides, 1981). Since protein phosphorylation is highly regulated by kinases,
protein kinases play critical roles in mediating multiple biological processes and
molecular functions, such as cell proliferation (Aithal, Toback, & Cryst, 1980; Cerda
et al., 2006; Kuninaka et al., 2007; Pelaia et al., 2007), apoptosis (Gabai, Mabuchi,
Mosser, & Sherman, 2002; Otani, Erdos, & Leonard, 1993) and protein
degradation (Cazarin, Andrade, & Carvalho, 2014; Lu et al., 1998; Mizuguchi et al.,
1988; Tai et al., 2017). Importantly, deregulation of protein kinases may induce
impaired cellular pathways and signal transduction, such as Wnt pathway (Ehyai
et al., 2015; Ohishi et al., 2015) and insulin signaling pathway (Numata et al., 2011;
Ohta et al., 2015; Sawada, Yamashita, Zhang, Nakagawa, & Ashida, 2014;
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Whelan, Dias, Thiruneelakantapillai, Lane, & Hart, 2010), which contributes to a
variety of human diseases, such as cancer (ElMokh et al., 2017; M. Li et al., 2017),
cardiovascular disease (Behr et al., 2003; Oudit et al., 2004) and type 2 diabetes
(Kume et al., 2016; Russo, Russo, & Ungaro, 2013; Sidarala & Kowluru, 2016).
1.1.2 The human kinome
In 2002, Manning et al (Manning, Whyte, Martinez, Hunter, & Sudarsanam,
2002), revealed a comprehensive discovery of protein kinase genes in human
genome, where they reported 518 protein kinases in total (516 protein kinase
based on their 2007 updates). The human kinome constitutes 1.7% of the human
genes. Among the 518 protein kinases, 478 kinases have a “typical” eukaryotic
catalytic domain, also known as eukaryotic protein kinase (ePK), containing 12
common subdomains which construct a highly conserved kinase catalytic core
(Hanks & Hunter, 1995); meanwhile, there are 40 “atypical” protein kinase (aPK)
which have the kinase activity but lack of the common eukaryotic catalytic domain
(also known as the kinase core) (Manning et al., 2002).
1.1.3 Importance of ePK and its classification
Numerous studies have implied that typical ePKs are essential for normal
cell signaling and responsible for pathogenesis of many human diseases. For
example, RAC-alpha serine/threonine-protein kinase (Protein kinase B or AKT) is
one of the very first discovered and extensively studied ePKs because AKT is able
to phosphorylate a range of substrates which are in charge of various critical
biological processes, such as cell growth, death and angiogenesis. In 1995,
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Burgering, B. M et al. (Burgering & Coffer, 1995) reported that AKT is directly
involved in phosphatidylinositol-3-OH kinase (PI3K) signaling cascade. During the
past few decades, PI3K/AKT signaling have been proven to participate in many
molecular functions and diseases (e.g., insulin signaling, diabetes, cancer, etc.);
For example: a) Farrar, C et al. (Farrar, Houser, & Clarke, 2005) revealed that
activation of PI3K/AKT pathway increased protein expression of insulin receptor
by 200% in protein repair deficient mice, which suggested that AKT is a key
regulator in insulin signaling pathway. b) A genetic study (Yin et al., 2017) showed
a significant associate of AKT gene level and type 2 diabetes in Chinese population
(248 T2D cases and 101 controls). c) Zhang, Y., et al. (Y. Zhang et al., 2017)
conducted a large proteogenomic study across more than 11,000 cancer samples
assigned to 32 cancer types (Figure 1-2), and they reported that multiple
oncogenic mutation in PI3K/AKT pathway which has been demonstrated to be
abnormal in multiple types of cancer.
The 478 ePks have been classified into 8 groups:
1. PKA, PKG, PKC families (AGC) (e.g., AKT);
2. Calcium/calmodulin-dependent protein kinase (CAMK) (e.g., Mitogen-activated
protein kinase 1);
3. Casein kinase 1 (CK1);
4. CDK, MAPK, GSK3, CLK families (CMGC) (e.g., Glycogen synthase kinase-3
alpha, Mitogen-activated protein kinase 8 or JNK1);
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5. Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases (STE) (e.g., Dual
specificity mitogen-activated protein kinase kinase 1);
6. Tyrosine kinase (TK) (e.g., insulin receptor, Tyrosine-protein kinase Fyn);
7. Tyrosine kinase–like (TKL) (e.g., Serine/threonine-protein kinase B-raf);
8. Other kinase (Other) that contains eukaryotic catalytic domain but does not
belong to any groups above.
The classification of typical ePKs was summarized in Table 1-1 (data source
from (Manning et al., 2002), reformatted table). As can be seen from Table 1, the
tyrosine kinase (TK) group comprised 90 kinases is the largest group; AGC, CAMK
and CMGC groups contain moderate number of kinases (63, 74, and 61,
respectively); STE, TKL and CK1 are in the lower end of the kinome (47, 43, and
12, respectively); Other group consists of relatively large number of kinases (83),
which also play key roles in cellular functions and signal transduction, such as
mitotic cell cycle progression regulated by serine/threonine-protein kinase Nek7
(Yissachar, Salem, Tennenbaum, & Motro, 2006).
1.1.4 aPKs also play critical roles
Forty atypical protein kinases have been categorized into 8 groups: PDHK,
Alpha, RIO, ABC1, BRD, PIKK, Other, and A6 (A6 was excluded from the most up
to date kinome database). The best well-studied aPK might be mammalian target
of rapamycin kinase (mTOR), which directly or indirectly regulates numerous cell
signaling pathways including PI3K/AKT pathway (Amin et al., 2008; Babchia,
Calipel, Mouriaux, Faussat, & Mascarelli, 2010; H. Zhang et al., 2007), MAPK
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signaling pathway (Aldonza et al., 2015; Dormond-Meuwly et al., 2011; Landau et
al., 2009), JNK signaling pathway (A. Kim et al., 2017; March & Winton, 2011;
Shanware et al., 2014). As an atypical protein kinase, mTOR does not contains a
classic kinase core as ePKs; however, mTOR has two distinct complexes,
mTORC1 (Raptor) and mTORC2 (Rictor), which exhibit different molecular
functions (Lipton & Sahin, 2014). Nissim Hay et al.,(Hay & Sonenberg, 2004)
reported that mTORC1 enhanced the protein synthesis by phosphorylating
number of downstream transcription factors and ribosome kinases (e.g.,
Ribosomal protein S6 kinase beta-1), and AKT, a downstream effector of insulin
receptor (IR)/insulin receptor (IRS)/PI3K pathway, was also a key mediator of
mTORC1 (Figure 1-3); however, the mTORC2, as Sarbassov et al., (Sarbassov,
Guertin, Ali, & Sabatini, 2005) described, could be an essential component to
phosphorylate Akt on Ser473, which demonstrated completely different cellular
activity from mTORC1 (Figure 1-4). Hence, although the aPKs lack of a typical
kinase core, they still exhibit strong regulatory impact on the cellular signal
transduction.
1.1.5 Other kinases (non-protein kinases)
Beyond the 518 protein kinases in human, there are also many other nonprotein kinases of which the three main classes (sugar kinase, nucleoside kinase
and liquid kinase) are discussed in this chapter. Far less researchers focus on nonprotein kinases (Maeda et al., 2006); however, some kinases in this category also
play critical roles in cell signaling, such as PI3K.
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1.1.5.1 Sugar kinases
Sugar kinases mainly control aerobic glycolysis which generates critical
energy for tumor cells, so minimizing the catalytic activities of these kinases (e.g.,
6-phosphofructo-2-kinase) could potentially inhibit the tumor growth (Chesney,
Clark, Lanceta, Trent, & Telang, 2015). The sugar kinases can be categorized into
4 groups: Hexokinases (HK), Ketohexokinases (KHK), 6-phosphofructo-2-kinase
(PFK2) and Galactokinase.
1.1.5.2 Nucleoside kinases
Nucleoside kinases catalyze the phosphorylation on 5’- hydroxyl group on
ribonucleosides, and they have been widely recognized playing important roles in
NAD salvage pathway (T. Zhang et al., 2009); however, their molecular functions
have not been fully understood. One of the well-studied nucleoside kinases,
adenosine kinase 1 (AK1), transfers the gamma-phosphate from a molecule of
ATP to adenosine resulting in a molecule of adenosine monophosphate (AMP).
AK1 is the key mediator to maintain the cellular energy homeostasis, and Amiri,
M., et al. (Amiri, Conserva, Panayiotou, Karlsson, & Solaroli, 2013) discovered that
AK9 also exhibits nucleoside diphosphate kinase activity.
1.1.5.3 Lipid kinases
Lipid kinases mainly phosphorylate lipids by adding a phosphate group, and
serve as important switches to “turn on and off” cell signaling. One of the best
known lipid kinases, PI3K, phosphorylates phosphatidylinositol-4,5-bisphosphate
(PIP2), to form phosphatidylinositol-3,4,5-trisphosphate (PIP3), which is a critical
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mediator in response to stimuli (i.e., growth factor, insulin), subsequently, activates
an extremely important downstream protein kinase, AKT (Guerrero-Zotano, Mayer,
& Arteaga, 2016). PI3Ks are heterodimeric enzymes including catalytic subunits
(p110) and regulatory subunits (p85), named based on their molecular weight. The
p85 subunit recruits by receptor tyrosine kinases (RTKs) directly, then the p110
subunit is activated by p85 resulting a fully functional PI3 kinase (Okkenhaug,
2013). Figure 1-5 (Martini, De Santis, Braccini, Gulluni, & Hirsch, 2014) showed
that the pathway initiated by RTK and PI3K involves in numerous crucial substrates
proteins (i.e., Phosphoinositide-dependent kinase-1, AKT, mTORC1, ERK1/2).
Hyper-activation and mutation of PI3K is very common in tumor cells and
tissues where cell growth and proliferation are promoted whereas programmed cell
death, apoptosis, is inactivated. Chen et al., (S. Chen et al., 2016) unveiled that
inhibited PI3K activity reduced the colon cancer stem cell growth via decreased
cell proliferation and increased cleaved caspase 3, which is a biomarker of cancer
cell apoptosis.
Hypoactive PI3K in diabetic animal or human models has been
demonstrated. Supplement nutrition D-chiro-inositol (DCI), an essential secondary
messenger in insulin signaling, was reported to significantly increase PI3K protein
abundance in liver and skeletal muscle of diabetic rats, and resulting in reduced
fasting plasma glucose and increased glycogen synthesis through PI3K/AKT
pathway (Gao et al., 2016).
1.1.6 Protein kinase catalytic core
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Protein kinases, transferring a gamma-phosphate to substrate proteins and
producing phosphorylated proteins, normally contain two types of domains, a
highly conserved catalytic domain (kinase core) and a regulatory Src Homology 2
(SH2) or a Src Homology 3 (SH3) domain. Proto-oncogene tyrosine-protein kinase
(Src), for example, has regulatory domains SH2 and SH3, and a tyrosine kinase
catalytic domain. The regulatory domains, acted as adaptors, allow the upstream
signaling protein binding, which activates the tyrosine domain; subsequently, the
active kinase core changed its conformation to allow ATP and substrate binding
(Thomas & Brugge, 1997). However, as Kornev et al., described (Kornev, Haste,
Taylor, & Eyck, 2006): not all the protein kinases have regulatory domains. cAMPdependent protein kinase (PKA), one of the first well characterized protein kinases,
is a protein complex composed of catalytic subunits (i.e., PRKACA) and regulatory
subunits. For example, PRKACA only contains a kinase core which includes an
N-terminal lobe (N-lobe) and a C-terminal lobe (C-lobe), and a cleft or hinge region
located between the N-lobe and C-lobe. The docking cleft is for ATP binding. In
Figure 1-6, upon PKA regulatory/activated protein binding, the subdomains of
kinase core change their orientation and form an active conformation of PKA,
which allows one molecule of ATP to specifically dock into the binding cleft.
There are several highly conserved residues and motifs in the kinase core
(C. Kim, Cheng, Saldanha, & Taylor, 2007). In the ATP binding cleft, N-lope forms
a very hydrophobic pocket for ATP adenine ring, and glycine-rich loop (P-loop)
forms a “lid” for three phosphate docking. One of the most important conserved
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residues in the ATP binding pocket is the lysine in the N-lope (e.g., K72 in PKA),
which stabilizes the alpha- and beta-phosphates in a low energy position in the
binding domain. In the C-loop, there are two important motifs, Asp–Phe–Gly (DFG)
motif and His–Arg–Asp (HRD) motif, which are highly conserved regions across
all 478 ePKs. Another essential residue for exert catalytic activity is the aspartate
(e.g., D184 in PKA) in the DFG motif, and D184 stabilizes the beta- and gammaphosphate through metal atoms, such as magnesium. DFG motif together with the
following two residues form a “magnesium-binding” loop that is also highly
conserved in the kinase core. DFG motif has two conformations, “DFG-in” and
“DFG-out”, where “DFG-in” is an active conformation that allows to form the
magnesium-binding loop while “DFG-out” is inactive conformation that hides the
conserved aspartate in the deep hydrophobic region prevents the three ATP
phosphates from binding to the cleft between N-lope and C-lope (Vijayan et al.,
2015). Therefore, inactive conformation of the kinase core (specifically DFG-out)
might hinge ATP binding. One example of taking advantage of the conserved DFG
motif: imatinib (Gleevec), one of most successful type II tyrosine kinase inhibitors
treating chronic myelogenous leukemia, favors the DFG-out conformation to keep
it from active (Figure 1-7) (Treiber & Shah, 2013). Another highly conserved motif
in the kinase core is HRD motif which contains the aspartate (Asp 166 in PKA)
responsible for correcting orientation of substrate peptides. The 2nd residue which
is apart from the aspartate in HRD motif to the C-terminal is another conserved
lysine (Lys168 in PKA, Figure 1-6), which directly interacts with gamma-phosphate
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in the ATP, and stabilizes the ATP binding. It plays a critical role in the gammaphosphate transferring.
Mitogen-activated protein kinase 1 (MAPK1 or ERK2) is a key functional
protein kinase in MAP kinase pathway, which has been known involving in
numerous biological processes (e.g., cell growth (Husain et al., 2001) and
apoptosis (Zhou et al., 2015)) and pathogenesis of human diseases (e.g., cancer
(X. W. Li, Tuergan, & Abulizi, 2015) and diabetes (Kinoshita et al., 2011)). MAPK1
has very similar kinase core as PKA demonstrated above, and contains serval
highly conserved residues: Lys54 in the N-lobe for ATP docking; Asp167 in DFG
motif for activating MAPK1; Asp149 and Lys151 in the HRD catalytic motif for
gamma-phosphate transferring (Figure 1-8).
In summary, a) N-lobe and C-lobe are forming the kinase core which
presents in all eukaryotic protein kinases; b) The cleft or hinge for ATP binding
contains multiple highly conserved domains: glycine-rich loop (ATP binding), DFG
motif (active or inactive conformation) and HRD (catalytic activity); c) Two lysine
residues (e.g., Lys72 in N-lobe and Lys168 in C-lobe, PKA) are highly conserved,
and stabilize and correct orientation of ATP binding. d) Active protein kinases very
likely form a perfect ATP binding microenvironment, conducting a successful
gamma phosphate transfer from ATP to substrate proteins.
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Figure 1-1. The Protein Kinase Complement of the Human Genome (Human
Kinome). Figure adapted from G Manning et al., Science. 2002.
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Figure 1-2. Diagram of somatic mutation and copy-number alteration (CNA)
frequencies involving components of the PI3K/AKT/mTOR pathway. Figure
adapted from Zhang et al., Cancer Cell, 2017.
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Figure 1-3. The regulation mTORC1 activity by insulin through
PI3K/AKT/mTOR pathway. Figure adapted from Hay, N. and N. Sonenberg,
Genes Dev, 2004.

Figure 1-4. The critical role of rictor-mTOR (mTORC2) in Akt/PKB activation
Figure adapted from Sarbassov et al., Science, 2005.
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Figure 1-5. Overview of PI3 kinase and Akt signaling pathway. Figure
adapted from Martini et al., Ann Med, 2014.

Figure 1-6. Diagram of known interactions between the protein kinase
catalytic core, ATP and a substrate in PKA. Figure adapted from Kornev et al.,
PNAS, 2006.
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Figure 1-7. DFG-In and -Out conformations of inhibitor bound ABL. Figure
adapted from Treiber, D. K. Shah, N. P. Chem Biol. 2013. (A) Type i tyrosine kinase
inhibitor, VX-680, favors “DFG-in” conformation; (B) Type ii tyrosine kinase
inhibitor, Imatinib, favors “DFG-out” conformation.

Figure 1-8. Diagram of the inferred interactions between the human ERK2
(MAPK1) kinase catalytic core residues, ATP, and the protein substrates.
Figure adapted from Kornev et al., PNAS, 2006.

16

.

Table 1-1 Classification of eukaryotic protein kinases (ePKs)
Group
Containing PKA, PKG, PKC families
Calcium/calmodulin-dependent protein kinase
Casein kinase 1
Containing CDK, MAPK, GSK3, CLK families
Homologs of yeast Sterile 7, Sterile 11,
Sterile 20 kinases
Tyrosine kinase
Tyrosine kinase–like

Other

Symbols
AGC
CAMK
CK1
CMGC

Number of kinases
63
74
12
61

STE
TK
TKL
Other

47
90
43
83

17

1.2 Skeletal muscle insulin resistance in obesity and Type 2 diabetes
1.2.1 Global epidemic: Obesity and Type 2 diabetes
Obesity, defined as Body Mass Index ≥ 30 kg/m2, is one of the world
epidemics: according to the datasheet from World Heath Organization (WHO),
there were almost two billion adults are overweight (BMI≥ 25 kg/m2), and more
than 600 million of these were obese in the world in 2014; what’s more, 41 million
children (under age of 5) were overweight or obese in the same year. The
population on the earth was 7.347 billion (World Bank, United States Census
Bureau) in 2015, which means approximately 28% of the world population were
overweight and 8.1% were obese. The prevalence of obesity in the United States
is even worse, 70.7% of U.S. adults population were overweight (including obesity);
more than one third (37.9%) U.S. adults were obese; 9.4% of children (age 2-5
years) in the U.S. were obese in 2013-2014, as reported by Centers for Disease
Control and Prevention (CDC). The trends of obesity prevalence in the U.S. has
been substantially increased during the past few decades. In Figure 1-9, only 1014% U.S. adults suffered obesity in 1990 and this number increased to around 20%
in 2000 (Figure 1-10); Surprisingly, the prevalence of obesity experienced rapid
upsurge to more than 35% among U.S. adults in 2010 (Figure 1-11). Therefore, it
is critical to prevent obesity and understand the cellular mechanism of obesity.
Obesity is a known risk factor for many diseases, such as diabetes (X. M.
Liu, Liu, Zhan, & He, 2015; Walsh & Vilaca, 2017), cardiovascular disease (X. M.
Liu et al., 2015; Ortega, Lavie, & Blair, 2016; Rippe & Angelopoulos, 2016), and
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some types of cancer (Cao & Giovannucci, 2016; Goodwin & Chlebowski, 2016;
Nunez, Bauman, Egger, Sitas, & Nair-Shalliker, 2017). Importantly, insulin
resistance has a strong correlation between obesity and type 2 diabetes (T2D)
(Lackey & Olefsky, 2016; Wu & Ballantyne, 2017). Diabetes is a world burden that
affects 422 million adults (age 18 years and above) global wide in 2014 (WHO
facts report); critically, lower limb amputation rates are 10 to 20 times higher in the
diabetic patients than normal population (Moxey et al., 2011). The global
prevalence of diabetes is steadily increasing from 4.7% in 1980 to 8.5% in 2014.
Similarly to the prevalence of obesity, the developed and rich countries, such as
the United States, have higher diabetes rates than the world average. In 2012,
National Health and Nutrition Examination Survey reported that 29.1 million people
(i.e., 9.3% of U.S. population) had diabetes, and 8.1 million people with diabetes
were not diagnosed. Importantly, approximately 95% of the diabetes were T2D
(CDC reported in 2014), which has been often undiagnosed and underestimated;
however, T2D may leads to a variety of serious medical complications (e.g., loss
of vision, heart diseases, stroke, renal diseases, low limb amputations) (Acosta et
al., 2000; Khalil, 2016; Papatheodorou, Papanas, Banach, Papazoglou, &
Edmonds, 2016; Porte & Schwartz, 1996). Moreover, the number of U.S. adults
with diagnosed diabetes has been increased from 5.1 million in 1980 to 21.3 million
in 2012 (Figure 1-12); especially, the percentage of diabetic population located in
the southeastern region of the U.S. has been elevated from 6.2% in 2000 to 15.2%
in 2012 (Figure 1-13).
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In summary, obesity and diabetes are global epidemics that affect a large
portion of the human population; especially, the United States. Years of studies
have demonstrated the clear link between insulin resistance, obesity, and type 2
diabetes.
1.2.2 Insulin resistance in skeletal muscle
Food intake leads to the increase of plasma blood glucose. In order to
maintain the plasma glucose level, insulin is produced in the beta-cells of the
pancreas and released to signal insulin sensitive tissues/organs to absorb
excessive plasma glucose. Human skeletal muscle is responsible for
approximately 75% of insulin-stimulated glucose uptake and is also the main site
where insulin resistance takes place in obesity and T2D (Bjornholm & Zierath,
2005; Zierath, Krook, & Wallberg-Henriksson, 2000). Using hyperinsulinemic
euglycemic clamp technique (Diamond, Jacob, Connolly-Diamond, & DeFronzo,
1993), researchers found that brain, splanchnic area, adipose tissues have similar
insulin-stimulated glucose uptake in T2D patients

and non-diabetic controls;

however, insulin-dependent glucose uptake in skeletal muscle tissue was
dramatically reduced among T2D subjects (Figure 1-14). These results suggested
that skeletal muscle resistance to insulin is a primary defect in T2D (DeFronzo,
2004).
1.2.3 Cellular mechanism of insulin resistance in skeletal muscle.
1.2.3.1 Cellular mechanism of Normal Insulin Signaling
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The principal pathways contributed to insulin resistance might be insulin
signaling pathways activated by the insulin receptor, and one of the most
extensively studied insulin signaling pathways is PI3K/AKT. The insulin signal
transduction begins with ligand (insulin) binding to the insulin receptor (IR) which
activates IR, a receptor tyrosine kinase. The activated IR phosphorylates insulin
receptor substrate 1 (IRS1) and tyrosine phosphorylated IRS1 recruits PI3K,
resulting in the activation of downstream kinases, such as AKT. Activated AKT
induces glycogen synthesis via inhibition of glycogen synthase kinase 3 (GSK3);
increases the glucose transporter type 4 (GLUT4) translocation to plasma
membrane by blocking the activity of AKT substrate of 160 kDa (AS160); and
promote the protein synthesis via activation of mammalian target of rapamycin
complex (mTOR) pathway (Figure 1-15) (Prada & Saad, 2013; Puigserver et al.,
2003; Sano et al., 2003; Taniguchi, Emanuelli, & Kahn, 2006).
1.2.3.2 Cellular mechanism of Insulin resistance in skeletal muscle
The molecular mechanism of skeletal muscle insulin resistance remains
unclear. In the IR-PI3K/AKT pathway, serval key regulatory protein kinases have
been well investigated. Knocking out Akt2, for example, in mice has been reported
to induce insulin resistance and metabolic syndrome (Cho, Mu, et al., 2001; Cho,
Thorvaldsen, Chu, Feng, & Birnbaum, 2001); similarly, George S and colleagues
(George et al., 2004), using genomic technique, revealed that a family with
mutation in kinase domain of AKT2 led to impaired insulin sensitivity (insulin
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resistance). These results implied that AKT2 is an essential modulator to
phosphorylate downstream proteins in insulin signaling.
IRS is an essential initiator in the upstream of insulin signaling. Figure 1-16
(Copps & White, 2012) showed the pathway initiated by IRS and three tyrosine
phosphorylation domains binding to p85 (subunit of PI3K), growth factor receptorbound protein 2 (GRB2) and SH2 domain-containing protein tyrosine
phosphatase-2 (SHP2), and reduced tyrosine phosphorylation of IRS1 has been
widely accepted (Copps & White, 2012) in insulin resistant states. In contrast,
several studies showed that serine/threonine phosphorylation of IRS1 was
significantly elevated in obese or T2D mice or rats, which suggests that increased
serine/threonine phosphorylation of IRS1 may reduce its binding capacity to PI3K,
and eventually inhibit AKT activity (Morino et al., 2005; Yu et al., 2002).
1.2.4 Inflammation of skeletal muscle insulin resistance in obesity
Skeletal muscle insulin resistance association with chronic inflammation
has been widely recognized (Hotamisligil, 2006; Lumeng & Saltiel, 2011; McNelis
& Olefsky, 2014; Osborn & Olefsky, 2012). Despite increasing evidence has
implied that skeletal muscle inflammation occurs in obesity, the molecular
mechanism is still not fully understood. Increased immune cells accumulating in
myocytes of obese and T2D individuals has been reported (Fink et al., 2014; Fink
et al., 2013; Khan et al., 2015; Patsouris et al., 2014; Varma et al., 2009), and high
fat diet increased macrophage markers in insulin resistant obesity (Boon et al.,
2015; Tam et al., 2014). One theory of skeletal muscle insulin resistance

22

development is the activation of immune cells in the myocytes. For example, in
figure 1-17, very few immune cells are resting in the skeletal muscle (panel A) in
lean muscle, while macrophages and T cells, releasing cytokines, infiltrate into
expand adipose depots (or called intermyocellular and perimuscular adipose
tissue, IMAT) in obese skeletal muscle, which causes inflammation (panel B) (Wu
& Ballantyne, 2017). The cytokines, including IFN-γ and TNF-α, can activate IκB
kinase/NF-κB (IKK/NF-κB) and JNK pathways. Evidence showed that IKK/NF-κB
pathway was elevated in obesity with T2D (Green, Pedersen, Pedersen, & Scheele,
2011), and overexpression of IKK induced insulin resistance (Yuan et al., 2001).
Furthermore, Hirosumi J and colleagues (Hirosumi et al., 2002) reported activated
JNK pathway in obese individuals with insulin resistance; similarly, Chiang et al.,
(Chiang et al., 2009) indicated that JNK signaling was increased in obese mice.
Therefore, in figure 1-18, cytokines activated signaling pathways, such as IKK/NFκB, SAPK/JNK and JAK/STAT, impaired insulin sensitivity might via reduced
insulin-stimulated tyrosine phosphorylation and increased serine/threonine
phosphorylation of IRS (Wu & Ballantyne, 2017).
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Figure 1-9. Obesity trends among U.S. adults in 1990. Figure adapted from
CDC.

Figure 1-10. Obesity trends among U.S. adults in 2000. Figure adapted from
CDC.
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Figure 1-11. Obesity trends among U.S. adults in 2010. Figure adapted from
CDC.

25

Figure 1-12. Number of US Adults Aged 18 or Older with Diagnosed Diabetes,
1980-2012. Figure adapted from Diabetes Report Card 2014, CDC.
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Figure 1-13. Geographic Distribution of Diagnosed Diabetes in the United
States, 2000-2012. Figure adapted from Diabetes Report Card 2014, CDC.

27

Figure 1-14. Insulin-stimulated glucose uptake rates in various tissues in
human. Figure adapted from DeFronzo, R. A. Med Clin North Am, 2004.

Figure 1-15. PI3K/AKT signal transduction pathway of insulin signaling.
Figure adapted from Prada et al., Expert Opin Investig Drugs. 2013.
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Figure 1-16. Insulin signaling and feedback pathways initiated by IRS. Figure
adapted from Copps, K. D. White, M. F. Diabetologia. 2012.

Figure 1-17. Inflammation in skeletal muscle in obesity. Figure adapted from
Wu, H. Ballantyne, C. M. J Clin Invest. 2017.
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Figure 1-18. Inflammatory signaling mediates insulin resistance in myocytes
via IRS/AKT pathway. Figure adapted from Wu, H. Ballantyne, C. M. J Clin Invest.
2017.

1.3 Activity-based kinome profiling
Human kinome consists of more than 500 protein kinases which constitute
1.7% of human genome, so high-throughput protein kinases enriching and profiling
are highly demanded. Without kinome enrichment, traditional immunoblots
technique (i.e., western blotting) requires to probe one kinase at a time with
specific antibody against that kinase, and many kinases are not detectable due to
the low protein abundance in the complex matrix (e.g., muscle tissue). Despite the
immunoblotting is able to detect the protein kinases abundance, assessing the
active form of kinase (i.e., certain serine/threonine or tyrosine phosphorylation of
that kinase) might not be achievable due to lack of the phosphor-protein antibodies.
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Therefore, activity-based ATP probes were developed for high-throughput
enrichment of active protein kinases with the conserved kinase catalytic core,
specifically, the 478 ePKs in human kinome.
1.3.1 Kinase activity assay
The traditional kinase function/activity assays (e.g., radiometric filtration
binding assay, Figure 1-19) require radioisotope labeled ATP (H. Ma, Deacon, &
Horiuchi, 2008), as well as specific substrate proteins which may not be
commercially available. The enzyme activity is proportional for the utilized amount
of ATP, calculating by initial ATP subtracted by the remaining ATP after the
reaction. Other types of kinase functional assays are existing, such as
fluorescence intensity assay, fluorescence polarization assay, scintillation
proximity assay (von Ahsen & Bomer, 2005); yet, all the assays require prior
knowledge on the kinase of interest and availability of corresponding substrates.
1.3.2 Chemical structure and reaction of the activity-based probes
Quantitative proteomics is primarily used to assess protein abundance in
the cells or tissues; however, it becomes possible to detect proteins (enzymes)
activities by coupling with activity-based enzyme enrichment. In 1999, Yongsheng
Liu et al., (Y. Liu, Patricelli, & Cravatt, 1999) first synthesized the activity-based
chemical probes for serine hydrolases enrichment of which a biotinylated
fluorophosphonate (FP-biotin) was designed specifically for the active sites of
serine hydrolases (Figure 1-20). Researchers developed various activity-based
probe to assess enzyme activities (Bogyo, Verhelst, Bellingard-Dubouchaud, Toba,
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& Greenbaum, 2000; Greenbaum et al., 2002; Okerberg et al., 2005; Saghatelian,
Jessani, Joseph, Humphrey, & Cravatt, 2004).
In 2007, the same research group (Patricelli et al., 2007) synthesized novel
nucleotide acyl phosphates probes (also called kinase probes) that selectively bind
to ATP binding pocket (in the kinase core) of eukaryotic protein kinases (Figure 121). The kinase probes are constituted by an ATP group (adenosine ring and three
phosphates) which selectivity binds to the ATP binding cleft, an acyl phosphate
reaction group that forms an irreversible covalent bond with the conserved lysine,
and a six carbon linker with a biotin tag which can be pulled down by the biotin
affinity agarose beads (Avidin or Streptavidin). When the active-site directed
probes bind to the active kinases, the conserved lysine residues can be labeled
with biotin tags; subsequently, the labeled active kinases were digested by trypsin
(a digest enzyme that cleaves specifically on lysine and arginine residues), and
biotin tagged peptides of active kinases were enriched and analyzed by mass
spectrometry. Figure 1-22 indicated two conserved lysine residues which are
closed to the three phosphate groups in the ATP probe: one is K33 which is the
conserved lysine on the N-lobe to stabilize the orientation of alpha- and betaphosphates, and the other is K129 which is located at the catalytic loop (2nd residue
from HRD motif) and is key residue to transfer the gamma-phosphate to substrate
peptides. Both lysine residues are highly conserved in nearly all the ePKs.
Furthermore, the authors identified 3 conserved motif for kinase probe binding
(Figure 1-23), where the size of the letter in given position represented the
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proportion of that residue in the sequence; generally, bigger size of the letter the
higher degree of conservation. A1 panel represented the conserved lysine in Nlobe, and A2 & A3 panel showed the lysine in catalytic loop.
Since the discovery of the activity-based kinase profiling, increased studies
adopted this technique coupled with proteomics to perform kinase functional assay
at large scale. Patricelli, M.P. and colleagues (Patricelli et al., 2011) revealed
functional proteome of more than 200 native kinases against several well studied
kinase inhibitors. Using activity-base kinase probe, recently, Okerberg et al.,
(Okerberg et al., 2016) identified a novel tumor-specific active site of casein kinase
1α (CSNK1A1). Figure 1-24 showed peptide sequence of active site of CSNK1A1
(panel A) and ion intensity of the mutated active site of CSNK1A1 (panel B).
In summary, activity-based protein profiling selectively targets active site of
protein kinases, which allows for studying functional kinome in biological matrix.
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Figure 1-19. Diagram of radiometric filtration binding assay. Figure adapted
from http://www.perkinelmer.com.

Figure 1-20. Route for the synthesis of FP-biotin. Figure adapted from Liu et
al., PNAS. 1999.
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Figure 1-21. Structure and mechanism of kinase probes. Figure adapted from
Patricelli et al., Biochemistry. 2007.

Figure 1-22. Conserved lysine residues in Cyclin-dependent kinase 2. Figure
adapted from Patricelli et al., Biochemistry. 2007.
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Figure 1-23. Three highly conserved kinase probe binding motifs. (A1) ATP
binding site motif; (A2) Catalytic binding motif 1; (A3) Catalytic binding motif 2.
Figure adapted from Patricelli et al., Biochemistry. 2007.
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Figure 1-24. Analysis of a CSNK1A1 active-site peptide in both colon tumor
and matched control samples. Figure adapted from Okerberg et al., PLoS One.
2016.
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1.4 Mass spectrometry-based quantitative proteomics
Proteome represents complete set of proteins in organisms. Proteomics is
a technique, coupled with biology and mass spectrometry (MS), to identify and
quantify as many proteins as possible in organisms. Even though around 20,000
genes in human genome has been sequenced, how many proteins (est. 1,000,000)
and protein post-translational modifications in human remains unknown (Figure 125) (Mayne et al., 2016).
1.4.1 Protein immunoblotting versus MS-blotting
Protein immunoblotting (i.e., Western blotting) is one of the most commonly
used methods to assess protein abundance in biological matrix (S. F. Smith, 1989).
Western blotting starts with separating the protein mixture in SDS-PAGE system
based on their molecular weights, followed by primary antibody probing of the
target protein. Using secondary antibody (against the primary antibody) and
chemical substrate of the secondary antibody, the target protein can be visualized
by colorimetric detection or fluorescent detection. This approach has been used
as a fundamental method to study protein abundance and other properties in
biology, biochemistry, pathology, etc. Western blotting has numerous advantage
over other methods, for example, providing specific and accurate assessment of
target protein abundance in complex biological samples (Lustbader & Pollak,
1991). However, immunoblotting techniques are highly dependent on primary
antibody; as a result, low quality antibody or lack of specific antibody for bait protein
are limiting this method from high-throughput protein detection.
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For many years, genomics has been primarily used for high-throughput
gene mutation and sequencing study because methods for measuring proteins and
metabolites could not achieve the high-throughput and in-depth as genomics
techniques. However, quantitative proteomics started to provide global profiling of
thousands of proteins in few hours. In 2015, Richards et al., reported that a onehour MS run could identify more than 4,000 proteins in yeast (Richards et al., 2015).
The typical workflow for quantitative proteomics adapted the similar concepts of
protein immunoblotting. The first step is separating the proteins (or peptides)
mixture in high-performance liquid chromatography instruments (HPLCs). Second
step is to analyze the extremely accurate molecular weight of each protein or
peptides in a high resolution mass spectrometer (i.e., Oribtrap (Makarov, 2000)).
The last step is to search the mass spectra against the known databases
containing protein sequencing information (e.g., Uniprot). The protein abundance
usually need to be normalized by internal or external standards. One of the biggest
advantage of quantitative proteomics is that no specific antibody is required to
identify the target proteins, and it can identify and quantify hundreds/thousands of
proteins, protein phosphorylation and other post-translational modifications
(PTMs).
Another crucial application for quantitative proteomics (also known as MSblotting) is that MS-blotting could be applied for protein-protein interaction studies.
In figure 1-26, we compared the advantages of MS blotting over the traditional
immunoblotting. For the western blotting, bait protein and partner protein need to
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be probed separately; however, both bait and partner proteins can be identified by
MS-blotting simultaneously because MS doesn’t require antibody probing. What’s
more, in the protein-protein interaction experiments, the MS based method can
detect hundreds of protein interaction partners, and identify novel partners that
have not been found by the immunoblotting (Caruso et al., 2015).
1.4.2 “Bottom-up” proteomics
Today, proteomics is a powerful tool to profile comprehensive proteomes in
various biological samples (e.g., cells, tissues, blood, etc.) (Cheung & Juan, 2017;
W. Liu et al., 2017; Tsolis & Economou, 2017). Two basic classes of proteomics
analysis are commonly employed to system biology: “Top down” and “bottom-up”
proteomics where “top-down” means to analyze the intact proteins directly by MS
whereas “bottom-up” refers that proteins are first digested by specific protease
(e.g., trypsin), and the resulting peptides are analyzed by MS (Gregorich, Chang,
& Ge, 2014). The main defect of “Top-down” proteomics is that large protein
molecules are difficult to be separated, fractionated, and ionized. Therefore, “Topdown” proteomics is not commonly used for large scale profiling. In contrast,
“bottom-up” approach generates the relatively small peptides which can be easily
separated and analyzed by MS, and the raw MS files containing the peptides
information can be mapped and assigned to protein based on protein sequencing
databases; hence, “bottom-up” proteomics is a primary proteomics method for
high-throughput protein or/and PTMs profiling. For instance, Sacco, F. and
colleagues were able to map 8,000 proteins and more than 16,000
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phosphoproteins in breast cancer cells using “bottom-up” proteomics (Sacco et al.,
2016).
1.4.3 “SILAC” based quantitative proteomics
Stable isotope labeled amino acid in cell culture (also known as SILAC) has
been widely used for quantitative proteomics (Doherty, Hammond, Clague,
Gaskell, & Beynon, 2009; Duan, Kelsen, Clarkson, Ji, & Merali, 2010;
Schwanhausser, Gossen, Dittmar, & Selbach, 2009). In 2002, Ong et al., first
reported a SILAC method in which the two cell lines were cultured in two growth
media containing two different isotopic labeled amino acids, the light (leu-d0) and
heavy (leu-d3). Equal amount of the cell lysates from the light (leu-d0) and heavy
(leu-d3) media were combined and analyzed together in one single MS-run (Figure
1-27). Because of the high resolution mass spectrometer, light and heavy labeled
peptides were differentiated and compared their ion intensity in one MS raw file.
Proteins from the two different cell lines can be compared side by side, leading to
reduced experimental error.
In traditional SILAC experiments, up to three cell lines can be labeled and
compared simultaneously, which is known as multiplex SILAC labeling. Seyfried
et al., (Seyfried et al., 2010) reported to perform quantitative “SILAC” proteomics
to enrich Sumolyation in three cell lines. In order to apply this technique to the
biological samples that are difficult to be labeled, such as tissue or plasma, a novel
modified “SILAC” called super-SILAC was developed to explore the tissue based
proteomics (T. Geiger, Cox, Ostasiewicz, Wisniewski, & Mann, 2010; Neubert &
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Tempst, 2010; Pozniak & Geiger, 2014). Figure 1-28 is showing that the primary
human skeletal muscle cells were labeled by

13C
6

L-Arginine as heavy cells, and

the skeletal muscle tissues were not labeled (non-labeled tissues were considered
as light tissue). Then equal amount of heavy labeled cells was spiked into different
light tissue samples, and the ratio of light/heavy of each sample was obtained. The
relative quantification of the tissue samples was based on “ratio of ratio”
comparisons. Using Super-SILAC, Noberini, R. and T. Bonaldi (Noberini & Bonaldi,
2017) were able to largely profile histone post translational modifications in breast
cancer tissues.
In summary, super-SILAC based “bottom-up” proteomics is a promising
approach to accurately identify and quantify proteome and post translation
modification-proteome in complex biological tissue samples.
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Figure 1-25. Schematic representation of the flow of bottom-up proteomics.
Figure adapted from Mayne et al., Anal Chem. 2016.
.

Figure 1-26. Western blotting versus MS-blotting in the protein-protein
interaction studies.
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Figure 1-27. Diagram of SILAC labeling and workflow in MS. Figure adapted
from Ong et al., Mol Cell Proteomics. 2002.

44

Figure 1-28. A schematic of Super-SILAC. Take 13C6 L-Arginine as an example.
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CHARTER 2. HYPOTHESES, SPECIFIC AIMS AND
EXPERIMENTAL DESIGN
2.1 Hypotheses
Although skeletal muscle insulin resistance is a primary contributor to the
development of metabolic abnormalities and chronic diseases, such as type 2
diabetes (T2D), the molecular mechanisms of its pathogenesis remain elusive
(Abdul-Ghani & DeFronzo, 2009; Biddinger & Kahn, 2006; Cersosimo, MAndarino,
& DeFronzo, 2011; DeFronzo & Abdul-Ghani, 2011; B. B. Kahn & Flier, 2000;
Rask-Madsen & Kahn, 2012). A number of kinases, involved in insulin signaling,
have been shown to have abnormal protein abundance and/or activity levels in
insulin resistance (Taniguchi et al., 2006). However, these studies are mainly
performed in cell cultures or animal models, targeting only a limited number of
known kinases. The combination of kinase enrichment technologies with tandem
mass spectrometry based proteomics offers a powerful approach for studying
global profiles of kinases in human health and disease states. However, no
kinome profiling in insulin resistant skeletal muscle in humans have been reported
so far.

We hypothesize that there are abnormal kinome and kinome

inteactome profiles in skeletal muscle of insulin resistant human
participants (OBi) as compared to insulin sensitive subjects (LC). The goal of
the project is to identify novel kinase-based molecular mechanisms responsible for
skeletal muscle insulin resistance in humans, providing new kinase targets for
prevention and treatment of insulin resistance and T2D.
2.2 Specific aims
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Specific Aim 1: Assess differences in kinome profiles in skeletal
muscle from lean healthy insulin sensitive (LC) and obese insulin resistant
human participants (OBi).
Specific Aim 2: Assess differences in kinome-interactome profiles in
skeletal muscle from lean healthy insulin sensitive (LC) and obese insulin
resistant human participants (OBi).
2.3 Experimental design
In figure 2-1, the two specific aims described in the overall experimental
design flowchart demonstrate our research plan and strategy. Clinical studies were
performed as we described (Caruso, Ma, Msallaty, Lewis, Seyoum, Al-janabi,
Diamond, Abou-Samra, Højlund, et al., 2014). In brief, extensive subject
recruitments were followed by comprehensive screening tests (e.g., oral glucose
tolerance test (OGTT), body mass index (BMI), medical/health history, blood
chemistry, ECG, etc.) at the clinical research center at Wayne State University.
Eligible subjects underwent in-patient clinical tests: a 2 hour hyperinsulinemiceuglycemic clamp to assess insulin sensitivity with muscle biopsies. Muscle biopsy
was quickly cleaned of connective tissue and fat (~30sec). Biopsy was frozen in
liquid nitrogen and was used for kinome/kinome interactome analysis by the
Universal-SILAC approach developed in Dr. Yi’s laboratory (X. Zhang et al., 2014).
Briefly, the study started with biopsy homogenization and spike-in standards
(super-SILAC) to minimize experimental variation. The tissue and SILAC labeled
cell lysate mixture was desalted by Zeba spin desalting columns to remove the
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endogenous free ATP and salts in the lysis buffer. The desalted mixture lysate was
labeled with ActivX ATP probes with desthiobiotin tag in the present of MgCl2, while,
for the kinome interactiom study, half of the mixture lysate was not labeled with
ATP probes. Those lysate without labeling was served as a negative control for
eliminating non-specific binding.
For specific aim 1, the labeled proteins were denatured by 8M urea buffer
and subsequently reduced by dithiothreitol (breaking the disulfide bonds) and
alkylated by iodoacetamide. The proteins were digested by MS-grade trypsin at
37°C shaker overnight. The resulting tryptic peptides were pulled down by
streptavidin agarose resin which has high affinity to desthiobiotin to enrich ATP
probe labelled peptides (which were from active kinase since active kinases, but
not inactive kinases, can be labelled by the ATP probe). The peptides pulled down
were washed and eluted from the beads. Enriched ATP probe labelled peptides
were desalted by C18 ziptip and analyzed by HPLC-ESI-MS/MS, followed by
bioinformatics study using different databases (such as Ingenuity Pathway
Analysis, Kyoto Encyclopedia of Genes and Genomes and Reactome pathway
databases).
For specific aim 2, double amount of tissue and cells as kinome
enrichment in Aim 1 were homogenized. Then, half of the mixture (muscle and
SILAC cells) lysate were labeled with ActivX ATP Probe whereas the other half
won’t be labeled (serving as a negative control). Instead of trypsin digestion to
generate labeled peptide, we will first pull down ATP probe labelled proteins (in

48

this case, active kinases, or active kinome) as well as their kinase interaction
partners, or kinome interactome. Followed by IP lysis buffer washing, PBS washing
and HPLC-grade water washing, three times of each, kinases and their binding
partners were reduced and alkylated, then were digested by trypsin “on-beads”
overnight. The tryptic peptides were desalted by C18 ziptip, followed by HPLC-ESIMS/MS analysis and bioinformatics study.

Figure 2-1. Schematic diagram of clinical, biological, and proteomics studies.
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CHARTER 3. CLINICAL STUDY PROTOCOL AND
CHARACTERIZATION OF HUMAN PARTICIPANTS
3.1 Human participant recruitment and screening visit
The participants for this project were recruited and studied at the clinical
research center at the C.S. Mott Center for Human Growth and Development at
Wayne State University. We started with initial phone screening to exclude any
participants with significant diseases (i.e., cancer, type 1 diabetes, etc.) and inform
the subjects study protocol of this clinical research, also schedule them for first onsite visit (Visit 1).
During the visit 1, we hired or collaborated with licensed research nurses
(RN) and physicians who eventually determined the eligibility of participants and
later perform muscle biopsy during visit 2. Participants were consented first with
general introduction of our study and they had to sign the consent form which had
been approved by Wayne State University IRB. We excluded participants based
on our exclusion criteria, such as significant pulmonary diseases (e.g., COPD),
heart diseases, diabetes coma, and extreme obese (BMI>40). Participants also
had to pass the urine tests, ECG and routine blood tests. For example, participants
with significantly lower than normal hemoglobin and hematocrit were excluded
since they may have anemia that might cause bleeding problem during the muscle
biopsy procedure (Barany, 2005; Ribeiro-Alves & Gordan, 2014; Torimoto & Kogo,
2006).
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For the non-diabetic participants, we had to conduct OGTT which is a test
for diabetes diagnosis. Participants were fasting minimal 10 hours, and given
glucose tolerance test beverages containing 75g glucose (Thermo Fisher Scientific,
Inc) and we drew the blood every 30 minutes up to 2 hours for plasma glucose
measurement using YSI 2300 glucose analyzer (Belfiore, Iannello, & Volpicelli,
1998; Fujibayashi et al., 2015). We grouped the participants (non-diabetic, prediabetic or diabetic) based on three criteria, HbA1C value, fasting glucose and
blood glucose at 2 hours of the OGTT (Figure 3-1) (American Diabetes, 2012).
Participants who meet at least one of the three criteria are considered as diabetes,
a)

A1C≥6.5;

b)

Fasting

Plasma

Glucose≥

126mg/dl;

c)

2h-Plasma

glucose≥200mg/dl.
3.2 Hyperinsulinemic-euglycemic clamp and muscle biopsies.
The qualified participants were scheduled to the second visits for
hyperinsulinemic-euglycemic clamp, the gold standard for insulin sensitivity
measurement, and muscle biopsy. They had to be fasting at least 10 hours
overnight and stop anticoagulants, which may cause bleeding, 7 days prior to the
second visit. Hyperinsulinemic-euglycemic clamp was used to measure the insulin
sensitivity of skeletal muscle in vivo (Cusi et al., 2000; DeFronzo, Tobin, & Andres,
1979), as described in previous studies (Langlais et al., 2011; Yi et al., 2007). The
study started at approximately 8:30 AM (time -60 minute point) in the morning and
basal plasma glucose was measured. The blood was drawn through a catheter
placed in an antecubital vein on one arm, which was covered by a heating pad
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(60 °C), where we also infused saline to avoid dehydration. Another catheter was
placed on the other arm for insulin and glucose infusion. The muscle biopsy was
performed at -30 min with a percutaneous needle in vastus lateralis muscle of thigh
under local anesthesia (use lidocaine). Muscle biopsies were immediately washed
with ice-old saline containing proteases and phosphatases inhibitors, separated of
connective tissue and adipose tissue then frozen in liquid nitrogen. At time 0 min
point, we started the primed regular human insulin (Humulin R; Eli Lilly,
Indianapolis, IN) infusion at constant rate 80 mU/m 2/min and variably infuse 20%
d-glucose to maintain the plasma glucose at 90 mg/dl. The theory of
hyperinsulinemic-euglycemic clamp was described in Figure 3-2 that we
continuously infused very high dose of insulin for 120 minutes to overcome the
endogenous insulin effect and adjusted glucose infusion rate to target the plasma
glucose at roughly 90 mg/dl by monitoring the blood glucose every 5 minutes. The
average of glucose infusion rates during the last 30 minutes of the clamp (also
known as M value, glucose uptake rate mg/kg.min) is widely used in the literature
to represent the insulin sensitivity in skeletal muscle. The higher M value, the
higher insulin sensitivity and the lower insulin resistance, vice versa (Caruso, Ma,
Msallaty, Lewis, Seyoum, Al-janabi, Diamond, Abou-Samra, Hojlund, et al., 2014).
In Figure 3-3, more than 200 participants who completed our clamp studies since
2012

showed

significantly different

M-value

between

lean

group

and

overweight/obese and T2D groups; however, no significant change of M-value was
observed between overweight/obese and T2D group, which indicated that
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overweight/obese and T2D participants were insulin resistant but lean group
maintained normal insulin sensitivity.
3.3 Clinical characterization the 16 participants recruited in kinome/kinome
interactome study
Totally, 8 lean healthy insulin sensitive and 8 obese insulin resistant
participants were recruited this projects. In table 3-1, participants were matched
with gender (5 males and 3 females in each group) and age (28.13 years old in
lean group versus 33.00 years old in obese group, P>0.05). The BMI and
percentage of body fat of these two groups showed significant difference where pvalue of BMI was less than 0.001 and p-value of % Fat Mass was less than 0.05
(Figure 3-4); in contrast, their mean hemoglobin A1c % (HbA1c%), fasting blood
sugar and 2h OGTT were similar and all were below the ADA’s prediabetes and
T2D diagnosis cutoffs (Figure 3-5). OGTT was showed in Figure 3-6 where the
plasma glucose of both groups reached a peak value (~130 mg/dL) and went down
back to normal range at 2 hour time point, which means 8 lean and 8 obese
subjects had normal glucose tolerance. In Figure 3-7, fasting plasma insulin levels
were significantly elevated in obese insulin resistant subjects (p-value < 0.01),
which implied the obese participants suffered from hyperinsulinemia. The lipid
profiles were showed in Figure 3-8: A) the total cholesterol levels of obese
participants were slightly increased but not significantly changed; (B) the
triglycerides levels in insulin resistant obese participants were significantly
elevated (p-value<0.05); (C) the high-density lipoprotein (HDL) cholesterol, which
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may reduce the risk for cardiovascular disease and diabetes, was slightly but not
significantly decreased in obese versus lean healthy participants (Bauer et al.,
2017; Rhee, Byrne, & Sung, 2017; Sanguinetti et al., 2001); (D) however, the lowdensity lipoprotein (LDL) cholesterol, the known “bad” lipoproteins that could be an
indicator for risk of cardiovascular disease (McCormack, Dent, & Blagden, 2016;
Soltani et al., 2016) and has been observed to be elevated in obese and T2D
participants (Marin et al., 2015), was significantly increased in the insulin
resistance group compared to lean group (p-value < 0.05).
As described above, the hyperinsulinemic-euglycemic clamp was applied
to measure insulin sensitivity. The obese participants for the kinome project were
selected based on their M-value, which is the key parameter reflected the insulin
sensitivity, and we chose 8 obese participants with significantly low M-value and
thus insulin resistance. Figure 3-9 is showing the infusion rate of glucose which
compensated the high dose of insulin effect during the 120 minutes clamp. In the
diagram, lean group reached a peak infusion rate of glucose and went down to
stable stage while obese participants quickly reached to a much lower plateau than
lean group without a peak dose of glucose. In figure 3-10, showing the M-value
calculated based on the average of last 30 minutes glucose infusion rates, obese
participants with insulin resistance had significantly lower M-value than lean
healthy participants (p-value < 0.001).
In summary, 8 lean healthy participants with normal glucose tolerance,
insulin sensitivity, insulin and lipids, and 8 obese participants with normal glucose
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tolerance but hyperinsulinemia and insulin resistance were enrolled in this
kinome/kinome interaction partner study.

Figure 3-1. The established glucose criteria for the diagnosis of diabetes.
Figure adapted from American Diabetes Association (American Diabetes, 2012).

.
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Figure 3-2. Diagram of hyperinsulinemic-euglycemic clamp. Insulin infusion
starts at time point 0 minute with constant rate, and adjusted rate of glucose
infusion is to compensate the insulin effect. Plasma glucose was maintained at
90mg/dL.

Figure 3-3. Average M-value (mg/kg/min) of the participants completed clamp
study. M-value is indicating insulin sensitivity, and more than 200 subjects have
completed hyperinsulinemic-euglycemic clamp in our study since 2011.
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Figure 3-4. The BMI and percentage of body fat of the 8 lean and 8 obese
participants. Bar charts are given as mean ± SEM.

Figure 3-5. The HbA1c% and fasting glucose levels of the 8 lean and 8
obese. Bar charts are given as mean ± SEM.
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Figure 3-6. Oral glucose tolerance test (OGTT) of the 8 lean and 8 obese
participants. Scatter plots are given as mean ± SEM.
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Figure 3-7. Fast plasma insulin level in 8 lean and 8 obese participants.
(A) The scatter plots are showing the individual fasting plasma insulin (pmol/L) of
the 8 lean and 8 obese subjects. (B) The bar charts are representing the fasting
plasma insulin (pmol/L) in mean ± SEM.

Figure 3-8. Lipid profiles of the 8 lean and 8 obese subjects. Four panels
represent: (A) total cholesterol; (B) Triglycerides; (C) HDL cholesterol; (D) LDL
cholesterol.

59

Figure 3-9. Two-hour hyperinsulinemic-euglycemic clamp data points of the
8 lean and 8 obese participants. The blue line represents lean group and orange
line stands for obese group (scatter plots are given as mean ± SEM).

Figure 3-10. M-value of the 8 lean and 8 obese subjects.
(A) The scatter plots are showing the individual M-value (mg/kg/min) of the 8 lean
and 8 obese subjects. (B) The bar charts are representing the M-value (mg/kg/min)
in mean ± SEM.
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Table 3-1. Clinical characteristics of the 8 lean and 8 obese participants.
Gender (M/F)
Age (years)
BMI at V2 (kg/m2)
%Fat Mass
HbA1C (%)
Fasting blood suger (md/dL)
2h OGTT (mg/dL)
M value (mg/kg/min)
Fasting plasma insulin (pmol/L)
Tot Chol (mg/dL)
Triglycerides (mg/dL)
HDL Chol (mg/dL)
LDL Chol (mg/dL)
* p-value <0.05
* *p-value <0.01
* **p-value <0.001
Data are given as mean ± SEM

Lean (n=8)
5/3
28.13±3.06
22.74±0.68
16.95±3.16
5.00±0.11
87.34±1.04
104.65±6.15
10.22±0.79
19.39±3.13
140.38±14.75
48.50±14.27
60.25±5.77
72.00±11.65

Obese(n=8)
5/3
33.00±4.71
32.26±1.50***
27.10±3.38*
5.33±0.14
93.33±2.19
99.70±5.07
5.50±0.44
40.84±7.63**
166.50±10.30
89.63±14.57*
47.50±3.44
108.50±10.07*
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CHARTER 4. HUMAN KINOME PROFILING IN SKELETAL
MUSCLE INSULIN RESISTANCE
4.1 Introduction
Protein kinases are the key regulatory modules for variety of biological
processes, such as insulin signaling pathway, glucose metabolism and
inflammation pathways. Dysregulated protein kinases might induce impaired
signal transduction and diseases (e.g., insulin resistance, T2D). As described
above, typical protein kinases (or ePKs) have a core structure for catalytic activity,
and taking MAPK1 as an example in Figure 4-1, the protein kinase core (shared
by majority of typical protein kinases) contains: 1) a conserved lysine (K54), located
in N-lobe, for alpha- and beta-phosphates of the ATP binding; 2) a Glycine richloop (also known as phosphate-binding loop or P-loop) for ATP binding; 3) another
conserved lysine (K151), located in catalytic loop, for gamma-phosphate binding; 4)
a DFG motif which is important for kinase activity; 5) a HRD motif in the activation
loop which is also regulating the kinase activity, where the aspartate (D149) is
responsible for transferring the gamma-phosphate to substrate proteins. In Figure
4-2 (O. Hantschel & Superti-Furga, 2004), tyrosine-protein kinase Lck (Lck) is an
example for active conformation of protein kinase core where p-loop is in the “open”
position and DFG motif is also in “DFG-in” conformation; in contrast, Protooncogene tyrosine-protein kinase Src (Src) is demonstrating the inactive kinase
core where p-loop is in “closed” position and DGF motif is in “DFG-out”
conformation. The Lck and Src have very similar size (509 amino acids of Lck, 536
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amino acids of Src), ATP binding site (K273 in Lck and K298 in Src), and active
site (D364 in Lck, D389 in Src); thus, they shared very similar kinase core structure
which represents the active and inactive forms of most protein kinases.
The ActivX™ Desthiobiotin-ATP Probes, one type of the activity-based
protein profiling probes, consist of 1) a molecule of ATP which can be selectively
bound to the ATP binding cleft between the N-lobe and C-lobe; 2) an acyl
phosphate contain reaction group which can form a covalent bound with the
conserved lysine residues (either the one in ATP binding pocket or the one in
catalytic loop); 3) A desthiobiotin-tag which can be pulled down by streptavidin
(Figure 4-3).
Skeletal muscle insulin resistance is one of the main defects in T2D, and
the molecular mechanism of insulin resistance in human skeletal muscle has not
been fully understood. We hypothesized that abnormalities in active protein
kinases play key roles in insulin resistance. Therefore, we sought to globally enrich
active protein kinases in human skeletal muscle insulin resistance, and discover
the abnormalities of protein kinases may contribute to the cellular mechanism and
pathogenesis of insulin resistance.
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Figure 4-1. Protein kinase core of MAP kinase-1. (Figure adapted from Kornev
et al., PNAS, 2006).

Figure 4-2. Active and inactive protein kinase core.
Lck represents active conformation whearas Src represents inactive conformation
of kinase core. Figured adapted from Hantschel, O. Nature Reviews Molecular Cell
Biology, 2004.
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Figure 4-3. Chemical structure of the desthiobiotin-ATP probe. (Figure
provided by the vendor).

4.2 Materials and Methods
4.2.1 Primary human skeletal muscle cells for SILAC labelling
Ten to fifteen milligrams of freshly obtained human muscle biopsy were
washed 3 times with ice cold Phosphate-Buffered Saline (PBS, pH 7.4, catalog #
10010049, Invitrogen, Carlsbad, CA), and were transferred to a 100mm sterile cell
culture dish. The muscle tissue was placed in the center of the dish using sterile
forceps, and was minced finely using a small sterile scissors; subsequently, was
transferred into a 50 mL conical centrifuge tube with 20 mL digestion solution (0.05%
trypsin EDTA (catalog # 25200056, Invitrogen, Carlsbad, CA) in PBS). The tissue
was incubated for 60 minutes at 37 °C, and the tube was swirled vigorously every
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20 minutes. After the incubation, digested tissue pieces were centrifuged at 3000
rpm for 15 minutes, and the pellet was transferred to a new 50 mL conical
centrifuge tube with 10mL human skeletal muscle cells medium, where the based
medium was Dulbecco's Modified Eagle's Medium with 1.0 g/L glucose (DMEM,
catalog # 11885-092, Invitrogen, Carlsbad, CA) containing 20% Fetal Bovine
Serum (FBS, catalog # SH3039603, Fisher scientific, Hampton, NH), 1% PenicillinStreptomycin-Glutamine (catalog # 10378-016, Invitrogen, Carlsbad, CA), 1%
Non-essential Amino Acid (NEAA, catalog #11140-050, Lifetechnologies,
Carlsbad, CA), 1% sodium pyruvate (catalog # 11360-070, Lifetechnologies,
Carlsbad, CA), 50 μg /mL fetuin (catalog # F2379-1G, Sigma, St. Louis, MO), 10
ng/ML Epidermal growth factor (EGF, catalog # E5036-200UG, Sigma, St. Louis,
MO), 0.4 μg /mL dexamethasone (catalog # D4902-100MG, Sigma, St. Louis, MO).
The tissue was suspended and mixed 10 times with a 10mL pipette, following by
removal of the undigested tissue using a sterile filter membrane. The filtrate
containing myoblasts was plated in 100mm cell culture dishes, and primary
cultured cells were maintained in a cell culture incubator (37 °C, 5% CO2).
4.2.2 SILAC labeled skeletal muscle cells
The primary cultured human skeletal muscle cells were sub-cultured in
SILAC growth medium which labeled the cells with heavy isotopic amino acids
(e.g., lysine, arginine), which are essential for cell growth. The SILAC growth
medium included DMEM Media for SILAC (catalog # 88420, Thermo Fisher
Scientific, Waltham, MA), 20% dialyzed FBS for SILAC (catalog # 88440, Thermo
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Fisher Scientific, Waltham, MA), 0.1 mg/mL L-Lysine-2HCl, 4,4,5,5-D4 for SILAC
(catalog # 88438, Thermo Fisher Scientific, Waltham, MA), 0.1 mg/mL L-ArginineHCl,

13C , 15N
6
4

for SILAC (catalog # 89990, Thermo Fisher Scientific, Waltham,

MA), 1% Penicillin-Streptomycin-Glutamine (catalog # 10378-016, Invitrogen,
Carlsbad, CA), 10 ng/ML Epidermal growth factor (EGF, catalog # E5036-200UG,
Sigma, St. Louis, MO), 0.4 μg /mL dexamethasone (catalog # D4902-100MG,
Sigma, St. Louis, MO). After 6 doublings of SILAC medium culture, the cells were
collected by PBS. The cells were tested to be more than 95% labeled by lysine-4
(4 Da heavier than neutral lysine) and arginine-10 (10 Da heavier than neutral
arginine) using HPLC-ESI-MS/MS (Data not shown).
4.2.3 Active protein kinase enrichment for functional kinome
Approximately 60–80 mg frozen muscle biopsies from 8 lean control (LC)
and 8 obese insulin resistance (OBi) participants, and mixed SILAC labeled
skeletal muscle cells from 2 LC and 2 OBi subjects were homogenized using a
Next Advance Bullet Blender (Model BBY5E) and lysed by Pierce IP Lysis Buffer
(catalog # 87787, Thermo Fisher Scientific, Waltham, MA) with 8M urea (catalog
# BP169-500, Fisher scientific, Hampton, NH) and Halt™ Protease/Phosphatase
Inhibitor Cocktail (catalog # 78440, Thermo Fisher Scientific, Waltham, MA).
Protein concentration was measured by Bradford protein assay, where Coomassie
blue plus Kit with standard (catalog # PI-23236, Fisher scientific, Hampton, NH)
was used for this assay. For each sample, 1.0 mg tissue lysate spiked-in with 0.5
mg SILAC cell lysate (Four cell lines from 2 LC and 2 OBi were pooled first) was
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aliquoted. Then the mixed lysate went through Zeba™ Spin Desalting Columns,
7K MWCO, 5mL (catalog # 89891 Thermo Fisher Scientific, Waltham, MA) to
remove all the endogenous ATP. The filtrate lysate of 8 LC and 8 OBi were diluted
with reaction buffer (provided in Pierce™ Kinase Enrichment Kits, catalog # 88310,
Thermo Fisher Scientific, Waltham, MA) into 2 mg/mL, and incubated with 10 μL
of 1M MgCl2 at room temperature for 1 minute, followed by 10μM ActivX™
Desthiobiotin-ATP Probe (catalog # 88311, Thermo Fisher Scientific, Waltham,
MA) incubation at room temperature for 10 minutes. The probe labeled lysate was
diluted with 8M urea and underwent reduction (10mM dithiothreitol (DTT)
incubation for 30 minutes at 55 °C) and alkylation (50mM iodoacetamide (IAA)
incubation for 30min at room temperature in dark). Each sample was digested by
30μg trypsin Protease MS Grade (catalog # PI90058, Fisher scientific, Hampton,
NH) for 16 hours at 37°C. The resulting peptides were incubated with 50μL of 50%
High Capacity Streptavidin Agarose resin slurry (catalog # 20357, Thermo Fisher
Scientific, Waltham, MA) for 1 hour at room temperature on a mixing rotator;
subsequently, the resin was washed 3 times with lysis buffer, 3 times with PBS,
and 3 times with LCMS-grade water. The final enriched active protein kinase
peptides were eluted 3 times with 75 μL Elution buffer (provided in Pierce™ Kinase
Enrichment Kits). The eluted peptides were dried with a speedvac, and were
reconstituted with 0.1% TFA in water (catalog # LS119 1, Fisher scientific,
Hampton, NH) for HPLC-ESI-MS/MS.
4.2.4 HPLC-ESI-MS/MS analysis
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The active protein kinase peptides were isolated on a 75 μm ID and 400mm
long C18 reversed phase analytical column which was in-house packed with
ReproSil-Pur C18-AQ μm resin (Dr. Maisch GmbH). The HPLC (UltiMate 3000,
Thermo Fisher Scientific, Waltham, MA) was equipped with two nano-flow UHPLC
pumps (upper pressure limit 800 bar). A linear HPLC gradient, 2-35% phase B (0.1%
FA in acetonitrile, catalog # LS120 1, Fisher scientific, Hampton, NH) was used to
separate peptide mixture, where phase A was 0.1% FA in water (catalog # LS118
1, Fisher scientific, Hampton, NH). The LTQ-Orbitrap Elite tandem mass
spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled with a nano flex
electronic spray ion source was employed to analyze the isolated peptides.
The parameters of nano-ESI was optimized to ionize peptides: spray
voltage 2.0 kV, capillary temperature 200 °C, sheath/aux/sweep gas flow rate 0.
The MS instrument parameters were setup for “bottom-up” proteomics: 1) A full
survey scan 300-1650 Th was acquired using 240,000 resolution power at positive
mode; 2) The top 20 most intense the ion peaks were selected for fragmentation
(MS/MS) by collision-induced dissociation (CID) with 33.0 normalized collision
energy and 1.0 m/z isolation window; 3) 30 seconds dynamic exclusion, a time
window in which the same ions are not selected for MS/MS; 4) singly charged ions
were excluded for MS/MS.

4.2.5 Database search
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The raw MS files generated from Xcalibur (Thermo Fisher Scientific,
Waltham, MA) were searched against Uniprot human protein sequences
(05/16/2014 version, www.uniprot.org) using MaxQuant software (verison.1.3.0.5)
(Cox & Mann, 2008; Cox et al., 2009; Monetti, Nagaraj, Sharma, & Mann, 2011;
Neuhauser, Michalski, Cox, & Mann, 2012). In the MaxQuant, besides the default
variable modifications (Oxidized Methionine and acetylation at protein N-term), a
novel variable modification, Desthiobiotin K, was manually added in the searching
engine. The false discovery rate (FDR) for protein and peptides (at least 6 amino
acid length) were both set at 1%; the Enzyme type chose “Trypsin”; multiplicity was
set at 2 including light labels and heavy Arg10 & Lys4 labels; maximal 2 missed
cleavages were allowed; the parent ion mass tolerance was 5 parts-per million
(ppm) and fragment ion mass tolerance was 0.5 Da. The MaxQuant generated two
main files, a desthiobiotin K peptides file (providing sequence of modified peptides
with lysine sites and their intensity) and a protein group file (providing the kinase
protein intensity).
4.2.6 Active kinase lysine sites identification and quantification
To be considered as an active kinase identified in the study, at least one of
the two conserved lysine residues, one in the ATP-binding pocket and the other in
the catalytic domain, of the active kinase lysine sites had to be enriched directly by
the ATP-probe. To quantify and compare the active protein kinases between two
groups, the enriched lysine sites have to meet the following three rigorous criteria:
1) The localization probability of dethiobiotin modified lysine site must be greater
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than 0.75; 2) either identified in at least half of the biopsy samples (i.e., ≥ 8
samples), or identified only in at least half of biopsy samples of LC or OBi group
(i.e., ≥ 4 samples); 3) for the kinases identified in both groups, a fold change of
OBi/LC greater than 1.5 or less than 0.67 was required. The SILAC labeled heavy
lysine sites identified in at least 8 out of 16 samples were used as “Universal”
internal standard, and the total peak of the SILAC labeled lysine sites were
calculated in each sample. Then, the peak area of each kinase (PAi) was
normalized by the sum peak area of universal heavy labeled lysine sites in the
same sample:
Norm ∶ 𝑖 =

PA𝑖
Total peak area of SILAC labeled lysine sites identified in ≥ 8 samples

The normalized protein kinase lysine site intensity underwent log
transformation, and independent two-side t-test were employed to assess the
significant changes (P<0.05) of active protein kinases in skeletal muscle between
LC and OBi. For the kinases only identified in either LC or OBi, the fold changes
of the kinases were assigned as infinity (Figure 4-4) and were considered as
significant by default.
4.2.7 Bioinformatics
Pathway analysis of functional protein kinome were carried out by two
software packages: 1) David bioinformatics (Huang da, Sherman, & Lempicki,
2009; Huang et al., 2007) including variety of databases, such as Gene Ontology
(GO) (Ashburner et al., 2000; Gene Ontology, 2015), Kyoto Encyclopedia of Genes
and Genomes (KEGG) (Kanehisa & Goto, 2000; Ogata et al., 1999; Wixon & Kell,
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2000), Rectome Pathway database (Croft et al., 2011) and PANTHER Pathway
(Mi et al., 2017; Mi et al., 2005; Tang & Thomas, 2016); 2) Ingenuity Pathway
Analysis (Ingenuity Systems, Redwood City, CA) whose database consists of the
high quality knowledgebase of biological functions and molecular networks
manually curated by scientists (Jimenez-Marin, Collado-Romero, Ramirez-Boo,
Arce, & Garrido, 2009; Kramer, Green, Pollard, & Tugendreich, 2014). Due to the
lack of “gold standard” for pathway analysis, multiple software packages might
provide comprehensive analysis for functional kinome in skeletal muscle insulin
resistance.
4.3 Results
4.3.1 Largest functional kinome in human skeletal muscle
The desthiobiotin labelled lysine, K(de), of the identified protein kinases
were

manually

searched

using

Uniprot

database

which

provides

the

knowledgebase ATP binding lysine sites and the 2nd lysine site away from the HRD
motif toward the C-terminal (in catalytic domain) (Patricelli et al., 2007). Only
kinases identified with a desthiobiotin labelled known conserved lysine were
considered as active protein kinases. The modified sequence of the active kinases
showed high consistency with three known ATP probe binding motifs (Patricelli et
al., 2007). Totally, 71 active protein kinase lysine sites (assigned to 54 protein
kinases) were identified in the kinome enrichment (Table 4-1). Seventeen of the
54 kinases were enriched by both conserved lysine residues, and 7 out of the 54
kinases were only bound to lysine residue in the ATP binding pocket while 34
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kinases were only bound to the lysine residue located in the catalytic loop.
Apparently, the protein kinases with lysine located in catalytic loop were more likely
to be enriched by this desthiobiotin ATP probe. Since the reaction group on the
probe is more likely to react with the gamma-phosphate which is located closer to
the lysine in catalytic loop than the one in ATP binding site, it might be an
explanation for why this activity based probe favors the lysine within the catalytic
domain over the one in ATP binding site. Surprisingly, 53 of identified 54 protein
kinases were serine/threonine kinases; only one tyrosine protein kinase, epidermal
growth factor receptor (EGFR), was identified in this dataset. The reason could be
the low abundance of tyrosine kinases which only comprises less than 20% of the
total ePKs. Additionally, as can be seen in Table 4-1, relatively large protein
kinases

can

also

be

targeted;

for

example,

microtubule-associated

serine/threonine-protein kinase 2 (MAST2, sequence length: 1798 amino acids)
was bound to the lysine in catalytic loop, and EGFR (sequence length: 1210 amino
acids) was enriched on the lysine in the ATP binding site, which implied the high
selectivity of the ATP probes that target the active conformation of protein kinases.
In brief, we were able to identify 54 out of the total 478 ePKs (11%) in active
conformation, which is largest functional kinome in human skeletal muscle insulin
resistance to date.
Canonical pathway analysis on the identified 54 kinases showed MAP
kinase pathway, mTOR pathway, Insulin signaling pathway, JNK cascade, Wnt
signaling pathway, T cell receptor signaling pathway, etc., were significantly
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enriched (P-value < 0.05) (Figure 4-6), and many of the pathways have been
reported to regulate muscle function and contribute to the pathogenesis of insulin
resistance, obesity and T2D. For example, insulin signaling pathway is one of the
best known pathways directly regulates insulin sensitivity, and dysregulation of
insulin signaling cascade may lead to insulin resistance and T2D (Kubota, Kubota,
& Kadowaki, 2017; Mackenzie & Elliott, 2014). It is noted that enriched pathways
could share the same kinases which involve in multiple pathways; for example,
MAPK1 and EGFR were highly cited in various signaling pathways. Among the
identified kinases involved in insulin pathway, glycogen synthase kinase-3 beta
(GSK3β) has been extensively reported as negative regulator of glucose
homeostasis. GSK3β phosphorylates and inactivates glycogen synthase and thus
attenuates glycogen synthesis. In addition, accumulating evidence suggested that
dysregulation of mTOR signaling pathway may induce insulin resistance and T2D
(Deblon et al., 2012; Kleinert et al., 2014; Y. Ma et al., 2015; G. I. Smith et al., 2015;
Yin et al., 2017).
Since protein kinases are known key regulators in the biofunctions (Figure
4-7), multiple cellular functions were significantly enriched, such as cell activation,
apoptosis and migration, which indicated that the active kinome in skeletal muscle
is highly responsible for critical cell proliferation, differentiation and programmed
cell death. In addition, oxidative stress response and cellular response to stress
exhibited high level of significance (p-value < 0.001), which indicated that kinases
responsible for cellular stress and survival are highly active and maintain relatively
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high abundance in skeletal muscle insulin resistance. Furthermore, the kinases
regulated fatty acid oxidation which is essential for acetyl-CoA and NADH
generation (Houten & Wanders, 2010).
Protein kinases are increasingly recognized as drug targets by which
alternating kinase activity may correct the dysregulation of numerus substrates to
exert therapeutic effects treating the various diseases, such as cancer and
diabetes. Drugbank (www.drugbank.ca) is an open source database containing
8261 drug entries that either have been approved by the FDA, or are still under
experimental development or clinical investigational trails (Knox et al., 2011; Law
et al., 2014; Wishart et al., 2008; Wishart et al., 2006). A comprehensive drug
target search on the 54 functional protein kinases using Drugbank database
suggested that 267 drug-target entries were found. Among them, 28 entries were
FDA-approved drugs, 25 were under clinical investigation and 214 were
experimental drugs which comprised the largest portion of the chart, which was
expected that drug discovery and development requires substantial investments
and research efforts (Figure 4-7). Of interest, among the 28 FDA-approved drugtarget entries (Table 4-2), metformin-AMPK1 (PRKAA1) was identified as a known
anti-T2D agent targeting on AMPK. Metformin is the first line drug for T2D
treatment, according to Drugbank data, metformin acts as an AMPK inducer to
enhance AMPK activity and therefore improve insulin sensitivity. Interestingly,
almost half (13 entries) targeted on EGFR and severed as anti-tumor agents (i.e.,
tyrosine kinase inhibitor) which mainly treat non-small cell lung cancer (NSCLC).
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Due to the high similarities among protein kinases, one drug could target on
multiple kinases but the therapeutic effect of the none-target kinases are remain
unknown. For example, bosutinib, a Bcr-Abl kinase inhibitor for the treatment of
chronic myelogenous leukemia (CML), showed multi-target effect on other kinases
including calcium/calmodulin-dependent protein kinase type II subunit gamma
(CAMK2G), cyclin-dependent kinase 2 (CDK2), dual specificity mitogen-activated
protein kinase kinase 1 (MAP2K1), dual specificity mitogen-activated protein
kinase kinase 2 (MAP2K2) and mitogen-activated protein kinase kinase kinase 2
(MAP3K2). Despite a variety of anti-tumor agents primarily target on tyrosine
kinases, some drugs designed as serine/threonine kinase inhibitors; for instance,
trametinib, targeting on MAP2K1/MAP2K2, treats metastatic melanoma with BRAF
V600E or V600K mutations. Other types of drug was also identified, such as
lidocaine (local or regional anesthetic agent), lithium (mood stabilizer) and
acetylsalicylic acid (pain killer).
4.3.2 Significantly changed active kinases between lean insulin sensitive and
obese insulin resistant participants
The quantitative proteomics of functional kinome implied that 22 out of the
54 identified kinases significantly changed comparing LC and OBi group (p-value
< 0.05). Among them, 13 kinases exhibited up-regulated levels while 9 kinases
were down-regulated in OBi subjects. It is noted that 11 kinases were only
identified in OBi group, and 3 kinases were only identified in LC groups because
the protein abundance of these active kinases were too low to be detected in the
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other group. All the 22 significantly changed kinases were serine/threonine kinases
(Table 4-3). It is noted that this is the largest catalog of active protein kinases in
human skeletal muscle with a significant change between LC and Obi.
Ingenuity Pathway Analysis (IPA) of the 22 significantly changed protein
kinases was performed to identify which cell signal transduction pathways have
been significantly enriched, based on the criteria that minimum three kinases
identified in each pathway and p-value must be less than 0.0001. Interestingly, the
SAPK/JNK and IL-6 signaling were the pathway enriched with highest significant
levels (P< 1.0E-09), and multiple other pathways were also significantly enriched:
AMPK pathway; mTOR pathway; Type 2 diabetes signaling; ErbB signaling; ERK5
signaling; cytokine related pathways (i.e., IL-10 signaling, JAK pathway, STAT3
pathway, IL-17 signaling, IL-1 signaling, etc.); pathways related to oxidative stress
and free radicals (e.g., iNOS signaling), etc. Note that the cell signal transduction
pathways from different databases (i.e., KEGG and IPA) may contains slightly
different

entries

based

on

the

peer-reviewed

functional

studies

and

knowledgebase curated by scientists. In order to visualize the abnormalities of
function kinome involved in cell signaling and molecular functions, the quantified
protein kinases in human skeletal was manually mapped to several significantly
enriched pathways that covered most abnormal active protein kinases in OBi.
Importantly, we performed IPA on the 13 protein kinases with increased
activities and 9 kinases with decreased activities separately (Figure 4-9). For the
up-regulated protein kinases, JNK signaling, IL-6 signaling, pathway related to
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reactive oxygen species (ROS) in macrophages, apoptosis signaling were
significantly enriched (P-value < 0.001 and at least 3 kinases involved); on the
other hand, AMPK signaling, mTOR signaling, p38 MAPK signaling were
significantly enriched in the down-regulated kinases.
MAPK signaling pathway (downloaded from http://www.kegg.jp) (Figure 410), including 15 identified protein kinases, was color-coded according to the
differential change of functional kinome between OBi and LC. The MAP kinase
pathway from KEGG contains three sub-signaling pathways: classic MAP kinase
pathway (ERK1/2 pathway), JNK and p38 MAP kinase pathway (involves
simplified NF-κB signaling) and ERK5 pathway. First, we mapped EGFR,
serine/threonine-protein kinase B-raf (BRAF, also known as RafB), dual specificity
mitogen-activated protein kinase kinase 1 (MAP2K1, also known as MEK1), dual
specificity mitogen-activated protein kinase kinase 2 (MAP2K2, also known as
MEK2), MAPK1 (also known as ERK2) and ribosomal protein S6 kinase alpha-3
(RPS6KA3, also known as RSK2) in the ERK1/2 signaling pathway in which five
upstream regulatory kinases of ERK2 (including ERK2 itself) didn’t exhibit
significant changes; on the contrary, RSK2 was dramatically decreased in OBi.
The differences of six kinases between LC and OBi involved in ERK1/2 signaling
implied that the upstream signaling remains intact, but the substrate of ERK2 (e.g.,
RSK2) was suppressed and subsequently might inhibit downstream effectors’
activities (i.e., CREB) in the insulin resistance state. Second, there were 5
identified protein kinases mainly affect JNK signaling: mitogen-activated protein
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kinase kinase kinase kinase 4 (MAP4K4, also known as HGK), mitogen-activated
protein kinase kinase kinase 2 (MAP3K2, also known as MEKK2), mitogenactivated protein kinase kinase kinase 3 (MAP3K3, also known as MEKK3),
Mitogen-activated protein kinase kinase kinase MLT (MLTK), dual specificity
mitogen-activated protein kinase kinase 4 (MAP2K4, also known as JNKK1 or
MEK4). Among the 5 kinases, we observed 4 significantly increased kinases
except MLTK, which strongly suggested that JNK signaling was up-regulated in
the skeletal muscle insulin resistance. In addition, HGK is a upstream regulator
mediating NF-κB signaling pathway. Third, p38 MAP kinases pathway contained 4
identified kinases which were dual specificity mitogen-activated protein kinase
kinase 3 (MAP2K3, also known as MKK3), dual specificity mitogen-activated
protein kinase kinase 6 (MAP2K6, also known as MKK6), mitogen-activated
protein kinase 12 (MAPK12, also known as p38γ or SAPK3) and mitogen-activated
protein kinase 13 (MAPK13, also known as p38𝛿 or SAPK4). Although the
upstream kinases (MKK3 and MKK6) didn’t show significant changes, p38 MAP
kinases were reduced significantly in OBi. Last, no identified kinase directly
participated in ERK5 pathway, though crosstalk between MAP kinases may
indirectly regulate ERK5 pathway (IPA database includes MKK3/6 and RSK2 in
ERK5 pathway).
Similarly, in the color-coded Wnt signaling pathway (downloaded from
http://www.kegg.jp) (Figure 4-11), three kinases displayed enhanced activities:
casein kinase II subunit alpha (CSNK2A1, also known as CK2A1), casein kinase I
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isoform alpha (CSNK1A1, also known as CK1α), and calcium/calmodulindependent protein kinase type II subunit delta (CAMK2D); three kinases did not
show significant change: GSK3β, casein kinase II subunit alpha’ (CSNK2A2, also
known as CK2A2), calcium/calmodulin-dependent protein kinase type II subunit
gamma (CAMK2G); one kinase was down-regulated: calcium/calmodulindependent protein kinase type II subunit beta (CAMK2B). Note since CK2A1 and
CK2A2 are isoforms of CK2, so half of the CK2 block was colored in red (increased)
and half in yellow (no change). Similarly, CAMK2D, CAMK2G and CAMK2B are
different subunits of CaMKII, which was colored differently according to the
differential changes of its subunits in LC and OBi.
We

color-coded

mTOR

signaling

pathway

(downloaded

from

http://www.kegg.jp) (Figure 4-12) using the same approach described above to
map functional kinome in human skeletal muscle. Multiple protein kinases in the
mTOR signaling have been significantly suppressed, such as serine/threonineprotein kinase STK11 (STK11, also known as LKB1), 5'-AMP-activated protein
kinase catalytic subunit alpha-1 (PRKAA1, also known as AMPK1), 5'-AMPactivated protein kinase catalytic subunit alpha-2 (PRKAA2, also known as AMPK2)
and RSK2; while Raf, MEK, ERK1/2, and GSK3β did not exhibit significant
changes between LC and OBi.
Of interest, significantly changed protein kinases of AMPK signaling
pathway (adapted from IPA) was also highlighted. Totally, five kinases, AMPK1,
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AMPK2, p38γ, p38𝛿 and LKB1, were involved and all of them were significantly
decreased.
Protein

kinases

are

highly

regulated

by

other

kinases

or

autophosphorylation, a significant enriched functional kinome network of the
insulin resistance responsible active kinases was constructed by IPA (Figure 4-14).
The network is related to post translational modification and cell survival,
differentiation and proliferation with score 43 (highest scored network, maximum
molecules was set at 70), which contains 21 significantly changed kinases (11 upregulated kinases highlighted in red and 10 down-regulated kinases highlighted in
green) and 13 other known proteins/protein complexes in the IPA database but
were not identified in current study.
4.4 Discussion
Protein kinases, enzymes catalyzing phosphorylation, play critical roles in
numerous biological processes and molecular functions, such as insulin signaling,
glucose uptake, etc. On the other hand, dysregulation of protein kinases might
results in variety of unhealthy states and diseases (e.g., obesity, insulin resistance,
and T2D). Skeletal muscle insulin resistance has been well defined as a primary
defect of T2D. Currently, dysregulation of protein kinases have been reported to
lead to skeletal muscle insulin resistance; however, most of the studies only
focused on the protein abundance or phosphorylation of few protein kinases in cell
or animal models (Sakiyama, Usuki, Sakai, & Sakane, 2014; B. K. Smith et al.,
2013; Tunduguru et al., 2014). No high-throughput profiling of active protein
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kinases in skeletal muscle biopsies of obese insulin resistant participants has been
reported to date. The global functional kinome in human skeletal muscle insulin
resistance remains unknown. Therefore, we developed a platform combining
activity-based kinase enrichment technique and quantitative proteomics to profile
active protein kinases in human skeletal muscle in lean healthy subjects and obese
participants with insulin resistance, and sought to unveil novel functional kinome
responsible for insulin resistance and obesity. Compared to previous studies, the
main innovations were 1) profiling dozens of active kinases other than protein
abundance or phosphorylation sites of few kinases; 2) providing a direct and
relative global assessment of kinase activities in vivo other than traditional
radioactive kinase activity assay which requires binding substrates; 3) Improved
coverage and accuracy of quantitative proteomics using “Universal” SILAC; 4)
providing a comprehensive view of significantly enriched cell signaling pathways
by multiple bioinformatics databases. In contrast, the challenges of current study
were: 1) highly complex biological samples (i.e., skeletal muscle biopsy) with
multiple high abundant contractile proteins (i.e., myosin, nebulin, titin, etc.) may
interfere relative low abundant kinome profiling; 2) data dependent acquisition
mode of “shotgun” proteomics might miss extremely low abundant proteins
compared to target proteomics, which is more sensitive than shotgun proteomics
but with relative low throughput. This approach is applicable for functional kinome
enrichment in various biological samples in different species.
4.4.1 Inflammatory response pathways in skeletal muscle insulin resistance
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Increasing evidence suggests accumulation of immune cells (i.e., T
lymphocytes, macrophages, etc.) in skeletal muscle cells (myotubes) in obesity
with insulin resistance and T2D (Fink et al., 2014; Fink et al., 2013; Khan et al.,
2015; Patsouris et al., 2014; Varma et al., 2009). It is well established that
proinflammatory cytokines (e.g., TNFα, IL-1, IL-6) lead to inflammation via
inflammatory response pathways, such as JNK signaling, NF-κB signaling, IL-6
signaling, etc (Hou et al., 2008; Sanchez et al., 2012; Spiga et al., 2017; Zhong et
al., 2009). In present study, the pathway analysis (Figure4-8) of the 22 protein
kinases significantly changed in OBi compared to LC suggested that multiple
inflammatory response pathways (e.g., JNK signaling, IL-6 signaling, IL-10
signaling) have been significantly enriched.
JNK has been demonstrated as a critical mediator in insulin resistance and
obesity (Chiang et al., 2009; Hirosumi et al., 2002), Senn JJ (Senn, 2006) reported
increased JNK activity in insulin resistance myotubes, and Vijayvargia R and
associates (Vijayvargia, Mann, Weiss, Pownall, & Ruan, 2010) performed JNK
knockdown which enhanced the glycogen storage in skeletal muscle cells from
mice. In this study, we found 4 significantly increased active protein kinases
(JNKK1, MEKK2, MEKK3 and HGK) in JNK signaling pathway (Figure 4-10) in OBi.
JNKK1 directly phosphorylates and activates JNK, and JNNK1 is regulated by
MEKK2 and MEKK3 kinase activities. Also, HGK or MAP4K4 has been reported
to play a central role in JNK and p38 MAPK signaling, serving as an upstream
regulator (Yao et al., 1999). Serine/threonine-protein kinase 38 (STK38) was
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significantly increased in OBi (not on the KEGG mapped JNK pathway). Although
STK38 was reported as a negative regulator of JNK pathway by inhibiting
autophosphorylation of MEKK1/2 (Enomoto et al., 2008), other regulatory
compensation may also affect MEKK1/2 activity. Despite we did not observe active
JNK directly (might be low abundant), four upstream kinases (especially JNNK1)
of JNK with increased activities strongly suggested that JNK signaling was
activated in human skeletal muscle insulin resistance. It is noted that
hyperglycemia may induce JNK activity (Hein, Xu, Xu, & Kuo, 2016), however, JNK
activity could remain unchanged in the current study because the participants in
our study have normal glucose homeostasis (normal fasting plasma glucose,
HbA1c, and 2-h OGTT) even though their skeletal muscle is insulin resistant.
Although, overwhelming evidence implies up-regulated JNK signaling may reduce
insulin sensitivity or impair insulin signaling pathway via increased IRS1 S 307
phosphorylation (Henstridge et al., 2012; Sabio et al., 2010), Zbinden FH and
associates (Zbinden-Foncea, Raymackers, Deldicque, Renard, & Francaux, 2012)
reported that endurance exercise (likely increases insulin sensitivity) increased
JNK and p38 MAPK activity in skeletal muscle from mice with T2D, which seems
contrast from our finding and findings from other groups. However, physiological
and pathological of mice with T2D might be different from those of human, and
majority of the studies are still consistent with our results.
4.4.2 p38 MAPK signaling
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p38 MAPK signaling may also contribute to obesity linked insulin resistance.
Emerging evidence suggests that inhibition of p38 may results in impaired insulin
dependent glucose uptake in skeletal muscle and adipocytes (Sweeney et al.,
1999). Furthermore, Somwar et al., (Somwar et al., 2001) observed significantly
decreased GLUT4 translocation by p38 inhibitor in L6 rat skeletal muscle cells,
which suggested that p38 inhibitors impaired insulin stimulated glucose uptake
through a GLUT4 translocation manner. On the other hand, a study showed p38
inducer activated glucose uptake via AMPK-GLUT4 signaling and enhanced
insulin sensitivity (P. C. Geiger, Wright, Han, & Holloszy, 2005). However, based
on our literature search, no study has been conducted on active p38 MAPK in
insulin resistant skeletal muscle from obese participants. In this study, we identified
two p38 activation kinases, MKK3 and MKK6, which remained no change;
surprisingly, two out of four p38 MAPKs (p38γ and p38𝛿) were identified in our
dataset, and their kinase activity was significantly reduced, which supports the
decreased p38 activity may reduce the insulin-stimulated glucose uptake and
cause insulin resistance via impaired AMPK (which was found ~ 9.0 fold reduced
in our study) mediated glucose transport. Although the molecular mechanism of
down-regulated p38 in peripheral insulin resistance is incompletely understood, we
provided an evidence of attenuation of p38 MAPK signaling in human skeletal
muscle insulin resistance. Not surprisingly, controversial results still exist, for
example, it is reported that low dose oxidative stress transiently induced p38
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MAPK activity and resulted in insulin resistance in isolated rat skeletal muscle
(Diamond-Stanic et al., 2011).
4.4.3 Wnt pathway
Of interest, we identified 7 protein kinases in Wnt pathway, specifically, 4 in
Wnt canonical pathway and 3 in Wnt/Ca2+ pathway (Figure 4-11). Growing data
shows that Wnt signaling was important for development and carcinogenesis, and
inhibition of Wnt signaling could suppress various tumor growth (Demagny, Araki,
& De Robertis, 2014; M. Kahn, 2015; H. Liu et al., 2014; Morrow et al., 2016; Reno
et al., 2016; Uehara, Kage-Nakadai, Yoshina, Imae, & Mitani, 2015; W. Zhang et
al., 2016). In addition, Wnt signaling is also activated by anti-inflammatory
cytokines (such TGFβ) (Castellone & Laukkanen, 2017; Jardim, Poco, & Campos,
2017). In the canonical pathway, CK1, axin, adenomatosis polyposis coli (APC)
and GSK3β forms destruction complex which degrades β-catenin via ubiquitination.
In the absence of Wnt signaling (Wnt-off), CK1 and GSK3β constantly
phosphorylate β-catenin which subsequently undergoes protein degradation; on
the other hand, the destruction complex become inactive upon Wnt ligand binding
(Wnt-on), and β-catenin is activated and transferred to nucleus (Minde, Anvarian,
Rudiger, & Maurice, 2011; Minde, Radli, Forneris, Maurice, & Rudiger, 2013).
Previously reports indicated that beta-catenin gene expression was lower in
adipose tissue and skeletal muscle of subjects with low insulin sensitivity
compared to those with high insulin sensitivity subjects (Karczewska-Kupczewska,
Stefanowicz, Matulewicz, Nikolajuk, & Straczkowski, 2016). In present study, CK1,
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a key inhibitor of β-catenin, was significantly increased in OBi, so β-catenin might
be suppressed in OBi. Compelling evidence shows β-catenin plays critical role in
glucose homeostasis and insulin secretion. Early works (Dabernat et al., 2009)
indicated that deletion of β-catenin in mice islet cells induced severe dysregulation
of glucose homeostasis. Later on, Elghazi et al., (Elghazi et al., 2012) observed
that β-catenin knockout in pancreatic progenitors led to impaired glucose tolerance.
Recently, Sorrenson, B. and colleagues reported that reduced β-catenin gene
expression in β-cell could increase glucose-stimulated insulin secretion.
Furthermore, the molecular mechanism of CK1/β-catenin induced abnormal
insulin-dependent glucose disposal may be involved in muscle contraction and
interaction with actin cytoskeleton (Galli et al., 2012; Nagashima et al., 1997).
Therefore, we first reported that decreased CK1/β-catenin complex activity might
be

responsible

for

impaired

insulin

stimulated

glucose

uptake

and

hyperinsulinemia in insulin resistant skeletal muscle of obese participants. Noted
that some researchers observed up-regulated Wnt signaling in diabetes (GarciaJimenez, Garcia-Martinez, Chocarro-Calvo, & De la Vieja, 2014), which provided
other possible molecular mechanism of CK1/β-catenin complex regulating insulin
resistance and diabetes related pathways.
There were three CaMKII subunits involved in Wnt/Ca2+ pathway; however,
differential changes of them in OBi (one increase, one decrease and one no
change) were observed. CaMKII plays important role in skeletal muscle during
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exercise, and exercise induced more than 5 fold changes of phosphorylation at
Thr287 of CaMKII in skeletal muscle (Rose, Kiens, & Richter, 2006).
4.4.4 mTOR signaling pathway
As described in the introduction part, mTOR is an atypical kinase which
lacks of typical kinase catalytic core; therefore, current platform was not capable
to enrich active mTOR. As predicted, we did not identify mTOR itself but did identify
other upstream regulatory kinases which could affect mTOR activity (Figure 4-12).
Among the protein kinases mapped to mTOR pathway, some of them mainly
involved in AMPK signaling pathway (Figure 4-13), and rest of them primarily
participated in ERK1/2 pathway.
4.4.4.1 AMPK pathway
AMPK is a protein kinase regulated by AMP/ATP ratio in cellular
microenvironment, and it could boost ATP generation and reduce utilization of ATP
(Carling, Zammit, & Hardie, 1987).

Overwhelming evidence indicates AMPK

activity was overall attenuated in insulin resistance, obesity and T2D (Coughlan,
Valentine, Ruderman, & Saha, 2013; Dzamko et al., 2010; Gauthier et al., 2011;
Yamada, Lee, Pessin, & Bastie, 2010). However, whether AMPK exhibiting
reduced activity in skeletal muscle insulin resistance mostly yielded the
controversial results. Bandyopadhyay et al., (Bandyopadhyay, Yu, Ofrecio, &
Olefsky, 2006) suggested decreased AMPK level in skeletal muscle from obesity
and T2D; while Liong, S. and Lappas, M. colleagues reported activated AMPK in
pregnant women with gestational diabetes (Liong & Lappas, 2015). Similarly,
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exercise stimulated AMPK activity in skeletal is still filled up with mixed conclusions.
For example, McGee et al., (McGee et al., 2003) stated that acute exercise
significantly increased AMPK activity in insulin resistant skeletal muscle, but
Sriwijitkamol and associates reported attenuated AMPK activity after acute
exercise in skeletal muscle of obese participants with insulin resistance and T2D
(Sriwijitkamol et al., 2007). On one hand, numerous controversial studies of AMPK
activity in skeletal muscle insulin resistance exist; on the other hand, no study
directly assessing the active AMPK in skeletal muscle of obesity with insulin
resistance and hyperinsulinemia. Increasing data shows that AMPK is also
regulated by inflammation, ER stress and oxidative stress, which are typically
increased in obesity with insulin resistance and led to increased AMPK activity (C.
C. Chen et al., 2014; Gautam et al., 2016; W. Li et al., 2015; Manna & Jain, 2013).
In contrast, decreased AMPK activity reduces glucose uptake in skeletal muscle
insulin resistance and T2D. In Figure 4-13, we quantified active LKB1 and
AMPK1/2 which were decreased by 11.9 and 9.5 in OBi, representatively. LKB1 is
a well-defined AMPK positive regulator that directly phosphorylates AMPK (Forcet
& Billaud, 2007; Hardie, 2005; Rider, 2006; Sriwijitkamol et al., 2006) whereas the
two p38 MAPKs (decreased in OBi) indirectly mediate AMPK activity via MKK3 (no
change). Our results provided evidence that AMPK signaling pathway was
significantly attenuated in OBi compared to LC.
4.4.4.2 ERK1/2 signaling
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Another pathway mediated mTOR signaling is ERK1/2 pathway which is a
central axis for numerous molecular functions (e.g., cell proliferation and
differentiation) and cell signal transduction, such as insulin signaling. Multiple
studies of the ERK1/2 activity in skeletal muscle of obesity and T2D demonstrated
mix results. First, Krook et al., (Krook et al., 2000) reported no significant difference
of ERK1/2 activity compared lean subjects and T2D, and Cusi et al., (Cusi et al.,
2000) observed similar results in human skeletal muscle biopsies; in contrast,
other researchers observed increased ERK1/2 phosphorylation in basal state of
obesity and T2D (Bandyopadhyay, Yu, Ofrecio, & Olefsky, 2005). In present study,
RafB, MEK1, MEK2, and ERK2 did not show significant change; however, RSK2
was attenuated in OBi.
4.4.4.3 AMPK and ERK1/2 signaling crosstalk with mTOR signaling
For the active kinase in the AMPK and ERK1/2 pathway identified in the
study, only LKB1, AMPK1/2 and RSK2 were significantly changed (decreased) in
OBi compared to LC. Emerging evidence suggests that LKB1/AMPK complex is a
negative regulator of mTOR (Dong et al., 2013; D. Han, Li, Zhu, Liu, & Li, 2013;
Shaw et al., 2004); however, Han et al., observed unchanged mTOR activity with
impaired LKB1/AMPK in rat adipose tissue (J. Han et al., 2016). One of ERK1/2
downstream kinases, RSK2, directly phosphorylates ribosomal protein S6 (RPS6)
and Eukaryotic translation initiation factor 4B (EIF4B), and regulates cell
proliferation and differentiation. RSK2 inactivates GSK3β which is a negative
mediator for glycogen synthesis by which RSK2 is a positive regulator for insulin
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sensitivity (Sutherland, Leighton, & Cohen, 1993). MAPK stimulates the mTORC1
activity via RSK1/2 independently of PI3K/AKT pathway. Taken with the findings
in this study, mTOR signaling might remain unchanged because, based on the
literatures, LKB1/AMPK may up-regulate mTOR while RSK2 (positive regulator)
may down-regulate mTOR activity; however, numerous factors could also alter
mTOR signaling. Therefore, further validation of mTOR and other key protein
kinases are required.
4.5 Summary
In Specific Aim 1, from 8 lean healthy participants and 8 obese participants
with insulin resistance using activity-based ATP probes and quantitative
proteomics analysis, we identified 54 active protein kinases in human skeletal
muscle, which is the largest catalog of experimental determined active kinases to
date. Twenty-two out of the 54 active kinases displayed a significant change in
insulin resistant obese subjects, including the protein kinases regulate JNK
signaling, p38 MAPK signaling, Wnt signaling, AMPK signaling, ERK1/2 signaling
and mTOR signaling. We generated a relative global picture of functional kinome
in skeletal muscle insulin resistance, providing novel insights into abnormal
functional kinome and molecular mechanism of skeletal muscle insulin resistance.
These results may facilitate identifying new targets for treating metabolic diseases.
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Figure 4-4. Flowchart
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Figure 4-5. Significantly enriched canonical pathways for the 54 identified
protein kinases. Data label on the bar represents the number of protein kinases
participated in that pathway.
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Figure 4-6. Significantly enriched biological functions for the 54 identified
protein kinases. Data label on the bar represents the number of protein kinases
participated in that biofunction.
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Figure 4-7. Drugbank database search on the 54 identified protein kinases.
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Figure 4-8. Ingenuity pathway analysis on the 22 significantly changed
kinases. Data label on the bar represents the number of protein kinases
participated in that pathway.
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Figure 4-9. Ingenuity pathway analysis on the up-regulated kinases versus
the down-regulated kinases. Data label on the bar represents the number of
protein kinases participated in that pathway.
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Figure 4-10. Color-coded MAPK signaling pathway of functional kinome
according to their differences in LC and OBi. Figure of MAPK signaling pathway
was adapted from KEGG.
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Figure 4-11. Color-coded Wnt signaling pathway of functional kinome
according to their differences in LC and OBi. Figure of Wnt signaling pathway
was adapted from KEGG.
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Figure 4-12. Color-coded mTOR signaling pathway of functional kinome
according to their differences in LC and OBi. Figure of mTOR signaling
pathway was adapted from KEGG.
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Figure 4-13. Color-coded AMPK signaling pathway of functional kinome
according to their differences in LC and OBi. Figure of AMPK signaling pathway
was adapted from IPA.
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Figure 4-14. A significantly enriched functional kinome network of the
differential changed protein kinases in human skeletal muscle insulin
resistance. Color-coded network was output from IPA. Solid line is indicating
direct interactions and dashed line is indicating indirect interactions.
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Table 4-1. Identified 71 active protein kinase lysine sites in skeletal muscle
insulin resistance.

Gene
Name

Desthiobi
otin K
positions
within
proteins

Protein Name

Modified sequence

DLK(de)SNNIFLHEDL
TVK

CAMK2G

Serine/threonine-protein
kinase B-raf
Calcium/calmodulindependent protein kinase
type II subunit beta
Calcium/calmodulindependent protein kinase
type II subunit delta
Calcium/calmodulindependent protein kinase
type II subunit gamma

TSTQEYAAK(de)IINT
K

43

CDK16

Cyclin-dependent kinase 16

DLK(de)PQNLLINER

288

CDK16

Cyclin-dependent kinase 16

194

CDK2

Cyclin-dependent kinase 2

LTDNLVALK(de)EIR
DLK(de)PQNLLINTEG
AIK

CDK5

Cyclin-dependent kinase 5

DLK(de)PQNLLINR

128

CDK5

Cyclin-dependent kinase 5

33

CSNK1A1

Casein kinase I isoform alpha

CSNK2A1

Casein kinase II subunit alpha
Casein kinase II subunit
alpha'
Epidermal growth factor
receptor
Interferon-induced, doublestranded RNA-activated
protein kinase
Glycogen synthase kinase-3
alpha
Glycogen synthase kinase-3
beta

NRETHEIVALK(de)R
DIK(de)PDNFLMGIG
R
DVK(de)PHNVMIDH
EHR
DVK(de)PHNVM(ox)I
DHQQK

BRAF

CAMK2B

CAMK2D

CSNK2A2
EGFR

EIF2AK2
GSK3A
GSK3B

LCTGHEYAAK(de)IIN
TK
IPTGQEYAAK(de)IIN
TK

Binding K
type

578

Catalytic
Domain

43

ATP binding
Site

43

ATP binding
Site

129

138
158
159

IPVAIK(de)ELR

745

DLK(de)PSNIFLVDTK
DIK(de)PQNLLVDPD
TAVLK
DIK(de)PQNLLLDPDT
AVLK

416
246
183

ATP binding
Site
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
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MAP2K1

MAP2K1

MAP2K2

MAP2K2

MAP2K3

MAP2K3

MAP2K4

MAP2K4

MAP2K6

MAP2K6
MAP3K2
MAP3K3
MAP4K4
MAP4K5
MAP4K5
MAPK1
MAPK12

Dual specificity mitogenactivated protein kinase
kinase 1
Dual specificity mitogenactivated protein kinase
kinase 1
Dual specificity mitogenactivated protein kinase
kinase 2
Dual specificity mitogenactivated protein kinase
kinase 2
Dual specificity mitogenactivated protein kinase
kinase 3
Dual specificity mitogenactivated protein kinase
kinase 3
Dual specificity mitogenactivated protein kinase
kinase 4
Dual specificity mitogenactivated protein kinase
kinase 4
Dual specificity mitogenactivated protein kinase
kinase 6
Dual specificity mitogenactivated protein kinase
kinase 6
Mitogen-activated protein
kinase kinase kinase 2
Mitogen-activated protein
kinase kinase kinase 3
Mitogen-activated protein
kinase kinase kinase kinase 4
Mitogen-activated protein
kinase kinase kinase kinase 5
Mitogen-activated protein
kinase kinase kinase kinase 5
Mitogen-activated protein
kinase 1
Mitogen-activated protein
kinase 12

DVK(de)PSNILVNSR

192

Catalytic
Domain

K(de)LIHLEIKPAIR

97

ATP binding
Site

DVK(de)PSNILVNSR

196

Catalytic
Domain

101

ATP binding
Site

192

Catalytic
Domain

93

ATP binding
Site

231

Catalytic
Domain

PSGQIM(ox)AVK(de)
R

131

ATP binding
Site

LSVIHRDVK(de)PSNV
LINAL

181

Catalytic
Domain

M(ox)RHVPSGQIM(o
x)AVK(de)R

82

DIK(de)GANILR

482

DIK(de)GANILR
DIK(de)GQNVLLTEN
AEVK
DIK(de)GANILLTDHG
DVK
NVHTGELAAVK(de)II
K
DLK(de)PSNLLLNTTC
DLK
DLK(de)PGNLAVNED
CELK

491

K(de)LIHLEIKPAIR

DVK(de)PSNVLINK

HAQSGTIMAVK(de)R

DIK(de)PSNILLDR

155
142
49
151
155

ATP binding
Site
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
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MAPK13
MARK2
MARK3
MARK3
MARK4

MAST1

MAST2

MAST3
MINK1
MLTK
MST4
NEK6
NEK7
NEK7
NEK9
NEK9
OXSR1

PRKAA1

PRKAA1

Mitogen-activated protein
kinase 13
Serine/threonine-protein
kinase MARK2
MAP/microtubule affinityregulating kinase 3
MAP/microtubule affinityregulating kinase 3
MAP/microtubule affinityregulating kinase 4
Microtubule-associated
serine/threonine-protein
kinase 1
Microtubule-associated
serine/threonine-protein
kinase 2
Microtubule-associated
serine/threonine-protein
kinase 3
Misshapen-like kinase 1
Mitogen-activated protein
kinase kinase kinase MLT
Serine/threonine-protein
kinase MST4
Serine/threonine-protein
kinase Nek6
Serine/threonine-protein
kinase Nek7
Serine/threonine-protein
kinase Nek7
Serine/threonine-protein
kinase Nek9
Serine/threonine-protein
kinase Nek9
Serine/threonine-protein
kinase OSR1
5'-AMP-activated protein
kinase catalytic subunit
alpha-1
5'-AMP-activated protein
kinase catalytic subunit
alpha-1

DLK(de)PGNLAVNED
CELK
DLK(de)AENLLLDAD
M(ox)NIK
DLK(de)AENLLLDAD
M(ox)NIK
EVAIK(de)IIDK

85

EVAIK(de)IIDK

88

Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
ATP binding
Site

DLK(de)PDNLLITSM(
ox)GHIK

499

Catalytic
Domain

DLK(de)PDNLLITSM(
ox)GHIK

637

Catalytic
Domain

DLK(de)PDNLLITSLG
HIK
DIK(de)GQNVLLTEN
AEVK
WISQDKEVAVKK(de)
DIK(de)AANVLLSEQ
GDVK
DIK(de)PANVFITATG
VVK
DIK(de)PANVFITATG
VVK
AACLLDGVPVALK(de
)K

152
177
180

148

Catalytic
Domain
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
ATP binding
Site
Catalytic
Domain

152

Catalytic
Domain

56

ATP binding
Site

492
155
46
146
174
163
63

DIK(de)TLNIFLTK

178

LGDYGLAK(de)K
DVK(de)AGNILLGED
GSVQ

81

DLK(de)PENVLLDAH
MNAK

VAVK(de)ILNR
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PRKAA2

PRKAA2
RPS6KA1
RPS6KA2
RPS6KA3
RPS6KA3
SLK
SLK
STK10
STK11
STK24
STK25
STK38
STK38
STK38L
TNIK
TP53RK
ULK3
ULK3

5'-AMP-activated protein
kinase catalytic subunit
alpha-2
5'-AMP-activated protein
kinase catalytic subunit
alpha-2
Ribosomal protein S6 kinase
alpha-1
Ribosomal protein S6 kinase
alpha-2
Ribosomal protein S6 kinase
alpha-3
Ribosomal protein S6 kinase
alpha-3
STE20-like serine/threonineprotein kinase
STE20-like serine/threonineprotein kinase
Serine/threonine-protein
kinase 10
Serine/threonine-protein
kinase STK11
Serine/threonine-protein
kinase 24
Serine/threonine-protein
kinase 25
Serine/threonine-protein
kinase 38
Serine/threonine-protein
kinase 38
Serine/threonine-protein
kinase 38-like
TRAF2 and NCK-interacting
protein kinase
TP53-regulating kinase
Serine/threonine-protein
kinase ULK3
Serine/threonine-protein
kinase ULK3

DLK(de)PENVLLDAH
MNAK

VAVK(de)ILNR
DLK(de)PENILLDEEG
HIK
DLK(de)PENILLDEEG
HIK
DLK(de)PSNILYVDES
GNPESIR
DLK(de)PENILLDEEG
HIK
DLK(de)AGNILFTLDG
DIK
ETSVLAAAK(de)VIDT
K
DLK(de)AGNVLMTLE
GDIR
DIK(de)PGNLLLTTGG
TLK
DIK(de)AANVLLSEH
GEVK
DIK(de)AANVLLSEQ
GDVK

141

45
189
186
541
195
157
63
159
178
158
142

DIK(de)PDNLLLDSK

214

DTGHVYAMK(de)ILR

118

DTGHIYAMK(de)ILR
DIK(de)GQNVLLTEN
AEVK
FLSGLELVK(de)QGAE
AR
NISHLDLK(de)PQNIL
LS

119

EVVAIK(de)CVAK

44

155
40
139

Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
ATP binding
Site
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
ATP binding
Site
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Table 4-2. Twenty-eight FDA-approved drug-target entries on the functional
kinome in human skeletal muscle insulin resistance.
Gene
Name

Protein Name

Approved drug
name

Drug
Bank ID

5'-AMP-activated
protein kinase
Acetylsalicylic
PRKAA1
DB00945
catalytic subunit
acid
alpha-1
5'-AMP-activated
protein kinase
Adenosine
PRKAA1
DB00131
catalytic subunit
monophosphate
alpha-1
5'-AMP-activated
protein kinase
PRKAA1
Metformin
DB00914
catalytic subunit
alpha-1
Calcium/calmodulindependent protein
CAMK2G
Bosutinib
DB06616
kinase type II
subunit gamma
CDK2

MAP2K1

MAP2K1

MAP2K1

MAP2K2

MAP2K2

Cyclin-dependent
kinase 2
Dual specificity
mitogen-activated
protein kinase
kinase 1
Dual specificity
mitogen-activated
protein kinase
kinase 1
Dual specificity
mitogen-activated
protein kinase
kinase 1
Dual specificity
mitogen-activated
protein kinase
kinase 2
Dual specificity
mitogen-activated
protein kinase
kinase 2

Pharmacology
Treatment of mild to
moderate pain

Nutritional supplementation

Treatment of type II
diabetes mellitus, kinase
inducer
Treatment of chronic
myelogenous leukemia
(CML)

DB06616

Treatment of chronic
myelogenous leukemia
(CML)

Bosutinib

DB06616

Treatment of chronic
myelogenous leukemia
(CML)

Cobimetinib

DB05239

Treatment of metastatic
melanoma, MAPK inhibitor

Trametinib

DB08911

Treatment of metastatic
melanoma with BRAF V600E
or V600K mutations

Bosutinib

DB06616

Treatment of chronic
myelogenous leukemia
(CML)

DB08911

Treatment of metastatic
melanoma with BRAF V600E
or V600K mutations

Bosutinib

Trametinib
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EGFR

Epidermal growth
factor receptor

Afatinib

DB08916

EGFR

Epidermal growth
factor receptor

Cetuximab

DB00002

EGFR

Epidermal growth
factor receptor

Erlotinib

DB00530

EGFR

Epidermal growth
factor receptor

Gefitinib

DB00317

EGFR

Epidermal growth
factor receptor

Icotinib

DB11737

EGFR

Epidermal growth
factor receptor

Lapatinib

DB01259

EGFR

Epidermal growth
factor receptor

Lidocaine

DB00281

EGFR

Epidermal growth
factor receptor

Necitumumab

DB09559

EGFR

Epidermal growth
factor receptor

Olmutinib

DB13164

EGFR

Epidermal growth
factor receptor

Osimertinib

DB09330

EGFR

Epidermal growth
factor receptor

Panitumumab

DB01269

Trastuzumab

DB00072

Vandetanib

DB05294

Lithium

DB01356

EGFR
EGFR
GSK3B

Epidermal growth
factor receptor
Epidermal growth
factor receptor
Glycogen synthase
kinase-3 beta

MAPK1

Mitogen-activated
protein kinase 1

Arsenic trioxide

DB01169

MAPK1

Mitogen-activated
protein kinase 1

Isoprenaline

DB01064

Treatment of metastatic
non-small cell lung cancer,
Tyrosine kinase inhibitor
Treatment of metastatic
colorectal carcinoma,
Tyrosine kinase inhibitor
Treatment of metastatic
non-small cell lung cancer,
Tyrosine kinase inhibitor
Treatment of metastatic
non-small cell lung cancer,
Tyrosine kinase inhibitor
Treatment of metastatic
non-small cell lung cancer,
Tyrosine kinase inhibitor
Treatment of metastatic
breast cancer, Tyrosine
kinase inhibitor
Treatment of Local or
regional anesthesia
Treatment of non-small cell
lung cancer, Tyrosine kinase
inhibitor
Treatment of metastatic
T790M mutation positive
non-small cell lung cancer
Treatment of metastatic
T790M mutation positive
non-small cell lung cancer
Treatment of EGFRexpressing, metastatic
colorectal carcinoma
Treatment of HER2-positive
breast cancer
Treatment of metastatic
medullary thyroid cancer
Mood stabilizer, kinase
inhibitor
Treatment of acute
promyelocytic leukemia
(APL),
Treatment of mild or
transient episodes of heart
block
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MAP3K2
RPS6KA3

Mitogen-activated
protein kinase
kinase kinase 2
Ribosomal protein
S6 kinase alpha-3

Bosutinib

DB06616

Acetylsalicylic
acid

DB00945

Treatment of chronic
myelogenous leukemia
(CML)
Treatment of mild to
moderate pain
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Table 4-3. Twenty-two significantly changed protein kinases in obesity with
insulin resistance.

Gene
Name

MAPK12
MAPK13
RPS6KA3

CAMK2B
STK11

PRKAA2

PRKAA1
MARK3
GSK3A

CAMK2D

MAP2K4
CSNK1A1
CSNK2A1
MAP3K2
MAP3K3

Protein Name

Mitogen-activated protein
kinase 12
Mitogen-activated protein
kinase 13
Ribosomal protein S6
kinase alpha-3
Calcium/calmodulindependent protein kinase
type II subunit beta
Serine/threonine-protein
kinase STK11
5'-AMP-activated protein
kinase catalytic subunit
alpha-2
5'-AMP-activated protein
kinase catalytic subunit
alpha-1
MAP/microtubule affinityregulating kinase 3
Glycogen synthase kinase-3
alpha
Calcium/calmodulindependent protein kinase
type II subunit delta
Dual specificity mitogenactivated protein kinase
kinase 4
Casein kinase I isoform
alpha
Casein kinase II subunit
alpha
Mitogen-activated protein
kinase kinase kinase 2
Mitogen-activated protein
kinase kinase kinase 3

Protein
ID

Desthiob
iotin K
positions
within
proteins

P53778

152

P53778

152

P51812

541

Q13554

43

Q15831

178

ATP binding
site
catalytic
domain

45

ATP binding
site

P54646

Binding K
Type
catalytic
domain
catalytic
domain
Catalytic
domain

Q13131

56

J3KNR0

85

P49840

246

ATP binding
site
ATP binding
site
catalytic
domain

E9PF82

43

ATP binding
site

P45985

131

P48729

138

P68400

158

Q9Y2U5

485

Q99759

491

ATP binding
site
catalytic
domain
catalytic
domain
catalytic
domain
catalytic
domain

Fold Change
OBi/LC
Mean ±
SEM
0
0
0

0.06 ± 0.01
0.08 ± 0.02

0.11 ± 0.03

0.11± 0.03
0.22 ± 0.07
0.30 ± 0.04

1.74 ± 0.55

4.51 ± 0.28
Infinity
Infinity
Infinity
Infinity
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MAP4K4
MINK1
NEK9
STK24
STK38
STK38L
TNIK

Mitogen-activated protein
kinase kinase kinase kinase
4
Misshapen-like kinase 1
Serine/threonine-protein
kinase Nek9
Serine/threonine-protein
kinase 24
Serine/threonine-protein
kinase 38
Serine/threonine-protein
kinase 38-like
TRAF2 and NCK-interacting
protein kinase

G5E948

155

Q8N4C8

155

Q8TD19

178

Q9Y6E0

158

Q15208

118

Q9Y2H1

119

Q9UKE5

155

catalytic
domain
catalytic
domain
catalytic
domain
catalytic
domain
ATP binding
site
ATP binding
site
catalytic
domain

Infinity
Infinity
Infinity
Infinity
Infinity
Infinity
Infinity
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CHARTER 5. HUMAN KINOME INTERACTOME
PROFILING IN SKELETAL MUSCLE INSULIN
RESISTANCE
5.1 Introduction
Protein kinases catalyze phosphorylation, one of the most important PTMs,
which serves as a switch to turn “on” and “off” of molecular functions. In most of
the cases, phosphorylated proteins (adding a phosphate group) become active or
“on” mode, dephosphorylated proteins (removing a phosphate group) become
inactive or “off” mode. Hence, protein kinases play essential roles in cell signal
transduction and biological process, such as insulin signaling, MAP kinase
signaling and glucose metabolic process. Protein kinases not only are key
regulators for downstream substrate proteins but also highly regulated by
phosphorylation; as a result, protein kinases are phosphorylated by other kinases
or themselves (also known as autophosphorylation). For example, protein kinase
B (or AKT) is highly regulated by upstream kinases, such as PDK1 and
mTOR/Rictor, which phosphorylate AKT at Thr308 and Ser473 (Tsuchiya, Kanno, &
Nishizaki, 2014). Receptor tyrosine kinases (i.e., EGFR) typically undergo
autophosphorylation where ligand binding leads EGFR dimerization and multiple
tyrosine residues are phosphorylated by EGFR (Bae & Schlessinger, 2010).
Therefore, intracellular protein-protein interactions of kinase-substrate complexes
and kinase-kinase complexes are primarily means but not limited to 1) cell
signaling events, such as promotion or inhibition of each other’s activity; 2)
transport across membranes, such as cytoplasm to nucleus transport; 3) protein
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degradation, such as ubiquitination. Dysregulation of protein-protein interactions
involving protein kinases might lead to cell signaling malfunction and diseases,
such as insulin resistance and T2D; nonetheless, large scale profiling of active
kinome interaction partners in human skeletal muscle insulin resistance remains
unreported.

Here, we hypothesized that abnormalities of functional kinome

interactome may exist in skeletal muscle of obese insulin resistant participants
compared to lean healthy insulin sensitive subjects. We developed a new activitybased functional kinome enrichment platform coupling with quantitative proteomics
to globally enrich and quantify interaction partners of active kinases in human
skeletal muscle in lean controls and obese insulin resistant participants.
5.2 Materials and Methods
5.2.1 SILAC labeled primary cultured human skeletal muscle cells
Ten to fifteen mg of each human muscle biopsy from two lean healthy and
two obese insulin resistance subjects were used to generate primary cultured
human skeletal muscle cells. Method used was the same as described in 4.2.1.
The primary cells were SILAC labeled with two heavy isotopic labeled amino
acids: L-Lysine-2HCl, 4,4,5,5-D4 (Lys4, which is 4 Da heavier than neutral
lysine) and L-Arginine-HCl, 13C6, 15N4 (Arg10, which is 10 Da heavier than neutral
arginine). Method used was the same as described in 4.2.2.
5.2.2 Active protein kinases enrichment for functional kinome interactome
Around 120–150 mg frozen muscle biopsy of each sample from 8 lean
control (LC) and 8 obese insulin resistance (OBi) participants, and SILAC labeled
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skeletal muscle cells as mentioned above were homogenized using a Next
Advance Bullet Blender and lysed by Pierce IP Lysis Buffer with 8M urea and
Halt™ Protease/Phosphatase Inhibitor Cocktail. Protein concentration was
measured by Bradford protein assay, where Coomassie blue plus Kit with standard
was used for this assay. For each sample 2.0 mg tissue lysate spiked-in with 1.0
mg SILAC cell lysate (four cell lines from 2 LC and 2 OB were pooled first) was
accurately aliquoted. Then the mixed lysate went through Zeba™ Spin Desalting
Columns, 7K MWCO, 5mL to remove all the endogenous ATP. The filtrate lysate
of 8 LC and 8 OBi were diluted with Reaction buffer into 2mg/mL, and incubated
with 10 μL of 1M MgCl2 at room temperature for 1 minute. Before the probe labeling,
each sample was evenly divided into two portions, one portion for real kinome
interactome enrichment while the other portion served as negative control (without
probe labeling to filter out non-specific binding proteins that are not labelled by the
probe but pulled down by streptavidin agarose resin). The portion for enrichment
was labeled with 10μM ActivX™ Desthiobiotin-ATP incubation at room
temperature for 10 minutes, whereas the negative controls were incubated with 10
μL ddH2O for 10 minutes. The probe labeled lysate and negative control were
incubated with 50μL of 50% high capacity streptavidin agarose resin slurry for 1
hour at room temperature on a mixing rotator; subsequently, the resin was washed
3 times with lysis buffer, 3 times with PBS, and 3 times with LCMS-grade water.
The agarose resin slurry with pulled down proteins were incubated with 10mM
dithiothreitol (DTT) for 30 minutes at 55 °C and 50mM iodoacetamide (IAA)

113

incubation for 30min at room temperature in dark. “On-beads” digestion was
performed with 2μg protease MS grade trypsin incubation for 16 hours at on a
thermo shaker at 37°C. The resulting peptides were dried with a speedvac, and
were desalted with Zipclean tips and reconstituted with 0.1% TFA in water for
HPLC-ESI-MS/MS analysis. Noted that all the catalog number and vendor
company are the same as described in 4.2.3
5.2.3 HPLC-ESI-MS/MS analysis
As described in 4.2.4
5.2.4 Database search
As described in 4.2.5
5.2.5 Bait active protein kinome and its interactome identification and
quantification
In the desthiobiotin K peptides file generated from MaxQuant software
package, which provides sequence of modified peptides with lysine sites and their
intensity, a bait kinase has to be identified with at least one of the two lysine
residues (#1 in ATP binding site and #2 in catalytic domain) on the desthiobiotin
modified lysine site. Because of the high selectivity and sensitivity of the ATP probe,
all the bait protein kinases were considered as in their active form. In order to unveil
true interaction partners of functional kinome, the identified proteins other than bait
proteins (i.e., active kinases in this case) must satisfied the following three rigorous
criteria: 1) the protein must be identified with minimum two unique peptides; 2) the
protein must be identified with light labeled peak area (PA) in at least half of the
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kinome interaction partner enrichments (i.e., ≥8 biopsy samples); 3) those proteins
must have an enrichment ratio (Kinome IP/negative control IP) of >10. In order to
calculate the enrichment, the PA for each protein identified was normalized against
Universal SILAC: the heavy labeled proteins identified in at least 8 out of 16
samples were used as “Universal” internal standard, and the total peak of the
SILAC labeled lysine sites were calculated in each sample. Then, the peak area
of each kinase (PAi) was normalized by the sum peak area of universal heavy
labeled proteins in the same sample:
Norm ∶ 𝑖 =

PA𝑖
Total peak area of SILAC labeled heavy proteins identified in ≥ 8 samples

Due to the sensitivity of this platform, non-specific binding partners may
result in high discover rate of false-positive. Therefore, we employed negative
controls without probe labeling to eliminate nonspecific binding accumulated in the
experiment process. The negative control concepts have been widely used and
accepted for protein-protein interaction partner identification in our previous work
(Caruso, Ma, Msallaty, Lewis, Seyoum, Al-janabi, Diamond, Abou-Samra, Hojlund,
et al., 2014; Caruso et al., 2015; X. Zhang et al., 2016). For each sample, the
enrichment ratio was calculated as followed: the average of SILAC normalized PA
from real enrichment pull down experiment was divided by the average of SILAC
normalized PA from negative control. It is noted that if zero identification in
negative control, then the enrichment ratio of that protein was manually assigned
as infinity. The calculation formula of enrichment ratio listed below:
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Enrichment_Ratio ∶ 𝑖 =

Average_Norm: 𝑖_IP
Average_Norm: 𝑖_control

In order to quantify relative protein abundance of the kinome interaction
partners, the PAj of each partner protein was normalized against PAj of total bait
kinases in the same sample. This normalization approach for protein-protein
interaction study has been demonstrated and employed in either quantitative
proteomics or western blotting (Caruso, Ma, Msallaty, Lewis, Seyoum, Al-janabi,
Diamond, Abou-Samra, Hojlund, et al., 2014; Caruso et al., 2015; Wepf, Glatter,
Schmidt, Aebersold, & Gstaiger, 2009; X. Zhang et al., 2016). The normalization
formula listed below:
Norm ∶ 𝑗 =

PAj
PAj_𝑡𝑜𝑡𝑎𝑙 𝑏𝑎𝑖𝑡 𝑘𝑖𝑛𝑎𝑠𝑒𝑠

To determine the significantly changed partners, a fold change of OBi/LC
greater than 1.5 or less than 0.67 was required, subsequently, p-value of
independent two-side t-test must be less than 0.05.
5.2.6 Bioinformatics
As described in 4.2.7
5.3 Results
5.3.1 Kinome interaction partners in human skeletal muscle insulin
resistance
To determine the true interaction partners of functional kinome in human
skeletal muscle insulin resistance, a rigorous identification and quantification
procedure was designed in figure 5-1. We first identified 1791 proteins with
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minimum two unique peptides and 0.01 false discovery rate (FDR) which has been
widely accepted for quantitative proteomics analysis for interaction partners
discovery (Wepf et al., 2009). Furthermore, we categorized 18 protein kinases,
being identified with at least one conserved lysine residue, which served as bait
proteins (Table 5-1); the rest 1773 proteins were potential prey proteins for the 18
active kinases. Then, in order to eliminate the nonspecific binding proteins, we
filtered 1580 proteins with enrichment ratios greater than 10. The true interaction
partners also need to be identified in at least half sample size (i.e., ≥ 8 muscle
biopsies); as a result, there were 616 proteins assigned as true interaction proteins
which were, based on our literature search, the first functional kinome interactome
in human skeletal muscle. The active kinases or active conformation of the kinases
are the real “players” in cellular functions because inactive kinases lose their
intrinsic enzyme activity or with very low catalytic level (Chihara-Nakashima,
Hashimoto, & Nishizuka, 1977; Phillips, Aponte, Covian, & Balaban, 2011; Ward
& O'Brian, 1992); therefore, the proteins interacted with active kinases are
important to understand the abnormalities of cell signaling and molecular function
in muscle insulin resistance.
First, we analyzed the 18 bait protein kinases which are the key modulators
in cell signal transduction. Among the 18 protein kinase, as expected from specific
aim 1, only one tyrosine kinase (Tyrosine-protein kinase CSK) was enriched, and
the other 17 kinases were all serine/threonine kinases. As we know, each
individual kinase may involve in multiple cell signaling pathway but, for most well
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studied kinases, has a few primary focuses; for example, AMPK1 is mainly
involved in AMPK pathway. Based on Uniprot and Gene Ontology databases, we
assigned the 18 protein kinases in 5 primary signaling pathways but 4 kinases
were not being assigned to any known signaling pathway based on the database
search (Figure 5-2). There were 5 protein kinases were mapped in the ERK1/2
pathway, which is also part of typical insulin signaling and mTOR signaling
pathway, and 3 kinases involved in AMPK pathway, which is also part of mTOR
signaling; two kinases participate in Wnt signaling; two kinases were assigned to
JNK pathway and two kinases involved in p38 MAPK signaling. Furthermore, a
biofunction analysis was performed on these 18 kinases (Figure 5-3). As we
expected 18 kinases showed phosphotransferase activity; in contrast, three
kinases displayed tyrosine kinase activity, but only 1 out of 3 was tyrosine kinase
and the other 2 kinases were serine/threonine kinases, serine/threonine-protein
kinase Nek6 (NEK6) and dual specificity mitogen-activated protein kinase kinase
6 (MAP2K6 or MEK6). MEK6 has been reported to phosphorylate both serine and
tyrosine residue on the p38 MAP kinases (Visconti et al., 2000). Due to the limited
number of bait kinases, a large bioinformatics analysis may not show significance
on many biofunctions, but these 18 kinases did involve in multiple foundational cell
signaling (Figure 5-2) which is highly related to insulin signaling (e.g., ERK1/2
pathway) and glucose uptake (e.g., AMPK pathway).
Second, we analyzed the 616 kinome interaction partners that directly or
indirectly bind to the bait active kinases. Noted that protein binding could be transit;
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therefore, this analysis may not contain the complete map of the interaction
proteome. Also, non-protein kinases and atypical kinases (without kinase core) or
other typical kinases, which are either in inactive conformation (“closed” ATP
binding site) or their ATP binding sites were blocked in the kinase-kinase
complexes, were also considered as interaction partners. Therefore, out of the 616
interaction partners, we identified 26 protein kinases (including 1 regulatory
subunit), 12 non-protein kinases, 2 protein phosphatases and 2 protein
phosphatase regulatory subunits (Table 5-2), such as MAPK1. MAPK3, tyrosineprotein kinase Fyn (FYN), tyrosine-protein kinase Yes (YES1), integrin-linked
protein kinase (ILK), cAMP-dependent protein kinase catalytic subunit alpha
(PRKACA), cGMP-dependent protein kinase 1 (PRKG1), hexokinase-1 (HK1),
TP53-regulating kinase (TP53RK), serine/threonine-protein phosphatase PP1alpha catalytic subunit (PPP1CA), protein phosphatase 1 regulatory subunit 12A
(PPP1R12A) and serine/threonine-protein phosphatase 2A 55 kDa regulatory
subunit B alpha isoform (PPP2R2A). Our finding indicated that dozens of kinasekinase interactions exist in human skeletal muscle.
Next, we conducted cell signaling pathway (Figure 5-4) and biofunction
analysis (Figure 5-5) on the 616 kinome interaction partners using IPA and David
bioinformatics online source integrating GOTERM, KEGG and Recatome
databases.

Diabetes pathway (from reactome database) was significantly

enriched with highest -log (p-value) at 15.44, and it covers 72 proteins that may
contribute to the pathogenesis of diabetes. For example, cAMP-dependent protein
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kinase type II-alpha regulatory subunit (PRKAR2A), (cAMP-dependent protein
kinase catalytic subunit alpha (PRKACA) and ras-related protein Rap-1b (RAP1B)
was categorized into diabetes pathway. Besides diabetes pathway, mTOR
signaling was also enriched with very high significant level. As we described above,
mTOR is a critical pathway regulates multiple key players that might involve in
insulin resistance and T2D, such as MAPK1, Growth factor receptor-bound protein
2 (GRB2), 40S ribosomal protein S3 (RPS3), 5'-AMP-activated protein kinase
subunit beta-2 (PRKAB2), eukaryotic translation initiation factor 3 subunit A (EIF3A)
and 40S ribosomal protein S6 (RPS6). Furthermore, insulin signaling pathway with
20 protein interaction partners (from KEGG database) was significantly enriched
as well. In addition, multiple essential signaling pathways were also significantly
enriched, including p70S6K signaling (downstream of mTOR), Wnt signaling, ILK
signaling, and apoptosis related pathway. Figure 5-4 illustrates the top 8 identified
pathways related but not limit to insulin signaling, cell growth and programmed
death, and diabetes.
The biofunction analysis of the kinome interactome indicated that protein
folding, proteasome, positive/negative regulation of ubiquitination and regulation
of cytoskeleton were highly enriched. These biofunctions are key molecular
processes for protein synthesis and degradation, and cytoskeleton remodeling.
Beyond those, glucose, pyruvate and glycogen metabolism play the central roles
in glucose homeostasis; similarly, fatty acid and lipid metabolism are critical
biological processes for lipid homeostasis. Taken all the biofunction analysis
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results, the kinome interaction partners participate in maintaining proteins, glucose,
and lipids balances in skeletal muscle, and might be contribute to abnormal
metabolism in obese individuals with insulin resistance.
5.3.2

Significantly changed functional kinome interaction partners in

skeletal muscle insulin resistance
Importantly, we identified 135 kinome interaction proteins with a fold change
greater than 1.5 (i.e., 83 proteins increased in OBi) or less than 0.67 (i.e., 52
proteins decreased in OBi) and also with significant p-value from independent twoside student t-tests (p < 0.05) comparing OBi with lean subjects. Of the 135
proteins, 131 were only identified in kinome IPs but not in negative control IPs,
which suggested the high confidence of the results. The 135 significantly changed
partners might be responsible for abnormal molecular function and cell signaling
caused by insulin resistance in skeletal muscle (Table 5-3).
Based on the pathway analysis for the interaction partners, we identified 20
proteins involved in the insulin signaling pathway, which is one of the most studied
pathways for abnormal molecular function and cell signaling related to insulin
resistance and T2D. We color coded insulin signaling pathway (downloaded from
http://www.kegg.jp) with identified partners in that pathway according to their
difference in kinome interaction; interestingly, out of the 20 kinome interaction
partners, 17 proteins remained unchanged and only 3 proteins (i.e., RPS6,
PRKAB2 and PRKAR2A) had significantly increased association to the active
kinases (Figure 5-7). Also, we mapped 16 interaction proteins in the MAPK

121

signaling pathway (downloaded from http://www.kegg.jp); similarly,13 proteins
remained intact and 3 partners showed enhanced interactions with active kinases
in OBi, which were heat shock-related 70 kDa protein 2 (HSPA2), Voltagedependent L-type calcium channel subunit beta-1 (CACNB1) and MAPT (Figure
5-8). Furthermore, two increased partners and 4 decreased in OBi compared to
LC were mapped into ILK pathway (downloaded from IPA software package) which
was significantly enriched in the pathway analysis for kinome interactome (Figure
5-8). In addition, two protein kinases with attenuated interactions to active kinases
in OBi were not categorized in any pathway above: YES1 (reduced 3.73 folds in
OBi) and TP53RK (reduced 2.67 folds in OBi), which play central roles in cell cycle,
cytokine responsive pathway and tumor cell differentiation and proliferation. In
addition, no phosphatase was identified with significant changes.
We performed biofunction analysis (Figure 5-6), which suggested abnormal
protein degradation and synthesis, apoptosis and cytoskeleton dynamics may
contribute to the pathogenesis of insulin resistance in human skeletal muscle. Of
interest, 5 out of the 6 proteins (i.e., PSMA1, PSMD14, PSMD11, PSMC3, PSMD7)
regulated ubiquitination were significantly increased, which might indicate a trend
for up-regulated ubiquitination in OBi.
To elucidate the protein-protein interaction of the 18 active bait kinases and
their 135 significant interaction partners, an interaction network was developed
using IPA with mapping parameter set at maximum 70 molecules per network
(Figure 5-6). We mapped 15 out of the 18 bait protein kinases (highlighted in
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yellow), 6 increased kinome interaction partner (highlighted in red) and 7
interaction proteins that showed decreased trend (highlighted in green) in the
network. The central core protein is ERK1/2, which has been identified as an
interaction partner of kinome, but did not show significant change. In the network,
we noticed a few proteins in the center were closely interacted with multiple
kinases (e.g., ERK1/2), such as integrin-linked protein kinase (ILK), vimentin (VIM),
RPS6, and microtubule-associated protein tau (MAPT).
5.4 Discussion
Intracellular protein-protein interactions mediated cell signal transduction,
protein transport, endocytosis and exocytosis of signaling molecules (e.g., insulin
granule exocytosis) have been widely accepted and recognized, and protein
kinases are known active reaction modules that interact with dozens of substrates
or regulatory proteins. High-throughput methods for protein-protein interaction
analysis have been broadly used, such as co-immunoprecipitation which allows
bait protein binding as well as the interaction proteins bound to the bait. However,
the typical Co-IP targets one bait protein which is specifically against the antibody
conjugated to the protein A/G beads. Here, we present an ATP probe pull-down
assay that enriches dozen of active protein kinases and their interaction partners
using activity-based ATP probes instead protein antibodies. Coupling high
resolution mass spectrometry with the ATP probe, we identified the first functional
kinome interactome (616 proteins) in the human skeletal muscle insulin resistance,
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which provided a global picture of kinase interaction complexes including kinasesubstrate, kinase-kinase, etc.
5.4.1 Insulin signaling pathway
Insulin signaling pathway is the central and most studied pathway that
affects insulin sensitivity and glucose metabolism; and dysregulation of insulin
signaling may result in insulin resistance and impaired insulin stimulated glucose
uptake. In this study, we identified and quantified 20 kinome interaction partners
involved in insulin signaling (Figure 5-8); and majority of them have unchanged
association with core active kinases in OBi. For example, the interaction to active
kinases for PPP1CA/PPP1CC (two catalytic subunits of protein phosphatase-1),
phosphorylase

b

kinase

regulatory

subunit

alpha

(PHKA1),

glycogen

phosphorylase (PYGB) which directly interact with each other (based on KEGG’s
data), remained the same in OBi. Also, GRB2 and ERK1 did not show significant
difference in their interaction to active kinases between LC and OBi. However,
multiple proteins in the insulin signaling pathway exhibited increased interaction
with active kinome, such as RPS6, PRKAB2 and PRKAR2A. Of interest, PRKAB2
(AMPK Subunit Beta-2), a non-catalytic subunit of AMPK1/2, which has been
shown down-regulated trend in our kinome profiling in Aim 1, has been reported
as a scaffold to assemble the AMPK complex which includes α (catalytic), β, and
γ subunits (Scott et al., 2004; Xiao et al., 2007). The molecular function of β subunit
of AMPK is far from well understood, and it is known that subcellular localization
and PTMs of AMPK can influence its activity (Salt et al., 1998; Warden et al., 2001).
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Qi et al., reported that ubiquitination of AMPK β subunit exert negative regulation
of AMPK1 activity in brown adipose tissue from mice (Qi et al., 2008); furthermore,
they proposed that elevated inflammation in the adipose tissue may lead to downregulated AMPK activity via increased PRKAB2 ubiquitination. In our study, we
also demonstrated up-regulated ubiquitination in OBi through the biofunction
analysis of the 135 significantly changed interaction partners. Therefore, our
finding suggested that increased PRKAB2 association with active kinome might
inhibit AMPK1 activity via the ubiquitin-proteasome protein degradation. It is noted
that researchers (Rubio, Vernia, & Sanz, 2013) also reported that sumoylation of
PRKAB2 enhanced AMPK activity, but they pinpointed that ubiquitination and
sumoylation shared the same catalytic lysine residue on PRKAB2, so these two
PTMs were competitive binding. Combining our data showing increased regulation
of ubiquitination, it seems that PRKAB2 might be a negative regulator of AMPK
activity in addition to be a scaffold subunit.
5.4.2 MAPK signaling pathway
MAPK signaling (Figure 5-9), including three sub-pathways: ERK1/2
signaling, JNK signaling and p38 MAPK signaling, is mainly responsible for cell
survival, differentiation and proliferation, and inflammation. We identified 16
kinome interaction partners assigned to MAPK signaling, primarily on ERK1/2
signaling (14 partners). GTPase HRas (HRAS) was identified as unchanged
partners, and Ras is one of the most important modulators in ERK signaling.
Additionally, two RafB regulators, Rap1 and PKA, were also identified, and the
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quantified results implied no significant change of Rap1 and PKA when interacting
with functional kinome. Combined with our results in specific aim 1 that EGFR,
RafB, MEK1, MEK2, ERK2 displayed no changed kinase activity, it seems that
ERK1/2 signaling pathway might remain intact in the insulin resistant skeletal
muscle, which is in agreement with some literature (Cusi et al., 2000; Krook et al.,
2000).
Interestingly, we found three kinome interaction partners (HSPA2, CACNB1
and MAPT) exhibited significant increased binding to active kinases, of which
CACNB1 displayed mixed kinome interaction (another subunit CACNA1S showed
no change). HSPA2, belonged to HSP70 family, is one of the most universal
molecular chaperones that assisting protein folding (Gehrmann et al., 2005; M.
Hantschel et al., 2000), and dysregulation of HSP70 leads to various diseases,
such as diabetes (Pockley, Henderson, & Multhoff, 2014). Growing evidence
indicates increased serum HSP70 level in diabetic patients (Garamvolgyi,
Prohaszka, Rigo, Kecskemeti, & Molvarec, 2015; Nakhjavani et al., 2010; Pagetta,
Folda, Brunati, & Finotti, 2003); however, its cellular mechanism in skeletal muscle
insulin resistance and T2D remains unknown. Previous data suggested that
HSP70 promoted muscle regeneration after injury and was responsive to
inflammatory cytokines. Emerging data reports that insulin resistance and obesity
induce inflammation in skeletal muscle (Hotamisligil, 2006; Lumeng & Saltiel, 2011;
McNelis & Olefsky, 2014; Osborn & Olefsky, 2012), and another theory of skeletal
muscle inflammation is that immune cells, secreting pro-inflammatory cytokines,
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are accumulating in myotubes (Wu & Ballantyne, 2017). Another study reported
that HSP70 activated T cells in autoimmune arthritis (Wieten et al., 2010), which
supports that the positive correlation between HSP70 and insulin resistance via an
inflammatory manner. The current finding that increased HSPA2 association with
functional kinome in OBi further supports HSP70’s role in skeletal muscle insulin
resistance.
5.4.3 ILK signaling pathway
Integrin-linked kinase catalyzes variety of intracellular and extracellular
functions, such as cell migration and proliferation, through integrin which is a
transmembrane receptors. In this study (Figure 5-10), we observed decreased
kinome interaction with ILK, myosin heavy chain 1 (MYH1), vimentin (VIM), actin,
cytoplasmic 2 (ACTG1), and increased kinome association level with nascent
polypeptide-associated complex alpha subunit (NANA), fibronectin 1(FN1). Of
interest, early work reported that ILK is necessary for PI3K mediated AKT signaling,
and ILK directly phosphorylates GSK3 (Delcommenne et al., 1998). Recent work
suggested that decreased glucose uptake and insulin sensitivity in ILK deficiency
mice in a GLUT4-dependent manner (Hatem-Vaquero et al., 2017). Based on our
literature search, only one study focused on the ILK function in development of
muscle insulin resistance, which was done in mice (Kang et al., 2016), nonetheless,
reduced kinome interaction with ILK has not been reported.
5.5 Summary
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We identified 616 functional kinome interaction partners in human skeletal
muscle from 8 lean healthy and 8 obese insulin resistant participants, which is the
largest human kinome interactome to date. Among the 616 interaction partners,
385 has a fold change > 1.5 or <0.67. Out of these 385 kinome interaction partners,
135 displayed significantly difference between the two groups (p-value < 0.05).
The kinome interatome participate in various cell signaling pathways (i.e., diabetes
pathway, mTOR pathway, insulin signaling pathway, etc.) and biofunctions (i.e.,
protein synthesis and degradation, cytoskeleton dynamics, and apoptosis).
Notably, we developed this ATP probe pull-down platform coupling with
quantitative proteomics, which allowed us to globally profile protein interaction
partners of dozens of active kinases simultaneously. However, the obvious
limitation was that interaction partners cannot be assigned to one particular kinase.
Nonetheless, using this approach, we generated the 1st active kinome interactome
profile in skeletal muscle of lean heathy individuals, and how it is differ in obese
insulin resistant subjects, which offers new information on molecular mechanism
of skeletal muscle insulin resistance.
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Figure 5-1. Flowchart of kinome interactome identification and quantification
procedure.
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Figure 5-2. Primary cell signaling pathways assigned for the 18 bait kinases.
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Figure 5-3. Biofunction analysis of the 18 bait kinases. Data label on the bar
represents the number of bait protein kinases participated in that biofunction.
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Figure 5-4. Signaling pathway analysis of the 616 functional kinome
interaction partners. Data label on the bar represents the number of protein
interaction partners participated in that pathway.
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Figure 5-5. Biofunction analysis of the 616 functional kinome interaction
partners. Data label on the bar represents the number of protein interaction
partners participated in that biofunction.
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Figure 5-6. Biofunction analysis of the 135 significantly changed functional
kinome interaction partners. Data label on the bar represents the number of
significantly changed protein interaction partners participated in that biofunction.
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Figure 5-7. Interaction network of the 18 bait protein kinases and
significantly changed functional kinome interaction partners. Solid line is
indicating direct interactions and dashed line is indicating indirect interactions.
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Figure 5-8. Color-coded insulin signaling pathway of kinome interaction
partners according to their differences in LC and OBi. Pathway map was
downloaded from KEGG.
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Figure 5-9. Color-coded MAPK signaling pathway of kinome interaction
partners according to their differences in LC and OBi. Pathway map was
downloaded from KEGG.
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Figure 5-10. Color-coded ILK signaling pathway of significantly changed
kinome interaction partners according to their differences in LC and OBi.
Pathway map was adapted from IPA.
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Table 5-1. Identified active protein kinase lysine sites (assigned to 18
kinases) served as bait proteins in kinome interactome profiling.

Gene
Name

CAMK2
D

Protein Name

Modified
sequence

Desthio
biotin K
positio
ns
within
protein
s

IPTGQEYAAK(de)II
NTK

CAMK2
G

Calcium/calmodulin-dependent
protein kinase type II subunit delta
Calcium/calmodulin-dependent
protein kinase type II subunit
gamma

CDK5

Cyclin-dependent kinase 5
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CSK
MAP2K
1
MAP2K
1
MAP2K
2
MAP2K
2
MAP2K
3
MAP2K
3
MAP2K
4
MAP2K
4
MAP2K
6
MAP2K
6

Tyrosine-protein kinase CSK
Dual specificity mitogen-activated
protein kinase kinase 1
Dual specificity mitogen-activated
protein kinase kinase 1
Dual specificity mitogen-activated
protein kinase kinase 2
Dual specificity mitogen-activated
protein kinase kinase 2
Dual specificity mitogen-activated
protein kinase kinase 3
Dual specificity mitogen-activated
protein kinase kinase 3
Dual specificity mitogen-activated
protein kinase kinase 4
Dual specificity mitogen-activated
protein kinase kinase 4
Dual specificity mitogen-activated
protein kinase kinase 6
Dual specificity mitogen-activated
protein kinase kinase 6
Serine/threonine-protein kinase
Nek6
Serine/threonine-protein kinase
Nek7

DLK(de)PQNLLINR
VSDFGLTK(de)EAS
STQDTGKLPVK
K(de)LIHLEIKPAIR
DVK(de)PSNILVNS
R

97

NEK6
NEK7

TSTQEYAAK(de)II
NTK

43

43

337

192

K(de)LIHLEIKPAIR
DVK(de)PSNILVNS
R

101

DVK(de)PSNVLINK
HAQSGTIMAVK(d
e)R

192

DIK(de)PSNILLDR
PSGQIM(ox)AVK(d
e)R
LSVIHRDVK(de)PS
NVLINALGQVK
M(ox)RHVPSGQI
M(ox)AVK(de)R

231

DIK(de)PANVFITA
DIK(de)PANVFITA
TGVVK

174

196

93

131
181
82

163

Binding K
type

ATP binding
Site
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
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NEK9
PRKAA1
PRKAA2
RPS6KA
1
RPS6KA
2
RPS6KA
3
ULK3

Serine/threonine-protein kinase
Nek9
5'-AMP-activated protein kinase
catalytic subunit alpha-1
5'-AMP-activated protein kinase
catalytic subunit alpha-2
Ribosomal protein S6 kinase alpha1
Ribosomal protein S6 kinase alpha2
Ribosomal protein S6 kinase alpha3
Serine/threonine-protein kinase
ULK3

LGDYGLAK(de)K

81

VAVK(de)ILNR

56

VAVK(de)ILNR
DLK(de)PENILLDEE
GHIK
DLK(de)PENILLDEE
G
DLK(de)PENILLDEE
GH
NISHLDLK(de)PQN
ILLSSLEKPHLK

45
189
186
195
139

ATP binding
Site
ATP binding
Site
ATP binding
Site
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
Catalytic
Domain
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Table 5-2. Kinases and phosphatases identified as functional kinome
interaction partners.
Gene
name
ALDH18A
1
BCKDK
CAMK2A
CAMK2B
CMPK1
CSNK2A1
CSNK2A2
EIF2AK2
FAM20B
FN3K
FN3KRP
FYN
HK1
ILK
MAPK1
MAPK3
MLTK
MYLK
MYLK2
NME1
NME2
PANK4
PFKL
PGAM5
PHKG2
PPP1CA
PPP1R12
A
PPP2R2A

Protein name

Category

Glutamate 5-kinase
[3-methyl-2-oxobutanoate dehydrogenase
[lipoamide]] kinase, mitochondrial
Calcium/calmodulin-dependent protein kinase type II
subunit alpha
Calcium/calmodulin-dependent protein kinase type II
subunit beta
UMP-CMP kinase
Casein kinase II subunit alpha
Casein kinase II subunit alpha
Interferon-induced, double-stranded RNA-activated
protein kinase
Glycosaminoglycan xylosylkinase
Fructosamine-3-kinase
Ketosamine-3-kinase
Tyrosine-protein kinase Fyn
Hexokinase-1
Integrin-linked protein kinase
Mitogen-activated protein kinase 1
Mitogen-activated protein kinase 3
Mitogen-activated protein kinase kinase kinase MLT
Myosin light chain kinase, smooth muscle
Myosin light chain kinase 2, skeletal/cardiac muscle
Nucleoside diphosphate kinase A
Nucleoside diphosphate kinase B
Pantothenate kinase 4
6-phosphofructokinase, liver type
Serine/threonine-protein phosphatase PGAM5,
mitochondrial
Phosphorylase b kinase gamma catalytic chain,
testis/liver isoform
Serine/threonine-protein phosphatase PP1-alpha
catalytic subunit

Non-protein kinase

Protein phosphatase 1 regulatory subunit 12A
Serine/threonine-protein phosphatase 2A 55 kDa
regulatory subunit B alpha isoform

Non-protein kinase
Protein kinase
Protein kinase
Non-protein kinase
Protein kinase
Protein kinase
Protein kinase
Non-protein kinase
Non-protein kinase
Non-protein kinase
Protein kinase
Non-protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase
Non-protein kinase
Non-protein kinase
Protein phosphatase
Non-protein kinase
Protein phosphatase
Protein phosphatase
regulatory subunit
Protein phosphatase
regulatory subunit
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PRKAB2
PRKACA
PRKACB
PRKAG1
PRKAR2A
PRKG1
PRPS1
PRPS1L1
SLK
STK24
STK38
STK38L
TP53RK
YES1

5-AMP-activated protein kinase subunit beta-2
cAMP-dependent protein kinase catalytic subunit
alpha
cAMP-dependent protein kinase catalytic subunit
beta
5-AMP-activated protein kinase subunit gamma-1
cAMP-dependent protein kinase type II-alpha
regulatory subunit
cGMP-dependent protein kinase 1
Ribose-phosphate pyrophosphokinase 1
Ribose-phosphate pyrophosphokinase 3
STE20-like serine/threonine-protein kinase
Serine/threonine-protein kinase 24
Serine/threonine-protein kinase 38
Serine/threonine-protein kinase 38-like
TP53-regulating kinase
Tyrosine-protein kinase Yes

Protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase regulatory
subunit
Protein kinase
Non-protein kinase
Non-protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase
Protein kinase
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Table 5-3. 135 significantly changed functional kinome interaction partners.
Gene
Name
ACOT9
ACSL3

ACTG1
AHCY
AHCYL2
ALDH4A1
ANXA1
ANXA6
APOBEC2
ARPC3
ATP1B1
ATP2B1
ATP5H
C14orf16
6

C1QBP
C22orf28
CACNB1
CAP2
CAPRIN1
CAPZA1
CBR1
CCDC56

Protein Name
Acyl-coenzyme A thioesterase 9,
mitochondrial
Long-chain-fatty-acid--CoA ligase 3
Actin, cytoplasmic 2;Actin,
cytoplasmic 2, N-terminally
processed
Adenosylhomocysteinase
Putative adenosylhomocysteinase
3;Adenosylhomocysteinase
Delta-1-pyrroline-5-carboxylate
dehydrogenase, mitochondrial
Annexin A1;Annexin
Annexin;Annexin A6;Annexin
Probable C->U-editing enzyme
APOBEC-2
Actin-related protein 2/3 complex
subunit 3
Sodium/potassium-transporting
ATPase subunit beta-1
Plasma membrane calciumtransporting ATPase 1
ATP synthase subunit d,
mitochondrial

Protein ID

Mean of fold
Change

SEM of Fold
Change

Q9Y305
O95573

0.308
0.186

0.05
0.04

P63261
P23526

0.309
0.260

0.08
0.02

Q96HN2

0.336

0.07

P30038
P04083
A6NN80

0.184
18.769
4.926

0.07
5.33
1.23

Q9Y235

20.517

8.05

O15145

5.195

1.69

P05026

4.363

0.90

P20020

0.419

0.10

O75947

7.243

2.77

UPF0568 protein C14orf166
Complement component 1 Q
subcomponent-binding protein,
mitochondrial
tRNA-splicing ligase RtcB homolog
Voltage-dependent L-type calcium
channel subunit beta-1
Adenylyl cyclase-associated protein
2
Caprin-1
F-actin-capping protein subunit
alpha-1
Carbonyl reductase [NADPH] 1
Coiled-coil domain-containing
protein 56

Q9Y224

55.310

21.12

Q07021
Q9Y3I0

15.448
7.119

5.93
2.54

Q02641

16.592

6.12

P40123
Q14444

11.697
4.540

4.13
1.23

P52907
P16152

0.083
4.371

0.01
0.75

Q9Y2R0

17.046

12.06
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CLIC4
CLPB
CMPK1
CYB5R1
DARS
DPM1
DYNC1I2
ECHS1
EEF1A1
EEF1A1P
5
EIF5A
EIF5AL1
ERP29
F13A1
FAM98A
FHOD1
FKBP3
FN1
GLIPR2
GLS
GSTK1
GSTM2
H1F0
HMGB1
HNRNPR
HRC
HSD17B1
0

Chloride intracellular channel
protein 4
Caseinolytic peptidase B protein
homolog
UMP-CMP kinase
NADH-cytochrome b5 reductase 1
Aspartate--tRNA ligase, cytoplasmic
Dolichol-phosphate
mannosyltransferase
Cytoplasmic dynein 1 intermediate
chain 2
Enoyl-CoA hydratase, mitochondrial
Elongation factor 1-alpha 1
Putative elongation factor 1-alphalike 3
Eukaryotic translation initiation
factor 5A-1
Eukaryotic translation initiation
factor 5A-1-like
Endoplasmic reticulum resident
protein 29
Coagulation factor XIII A chain
Protein FAM98A
FH1/FH2 domain-containing
protein 1
Peptidyl-prolyl cis-trans isomerase
FKBP3
Fibronectin;Anastellin;Ugl-Y1;UglY2;Ugl-Y3
Golgi-associated plant
pathogenesis-related protein 1
Glutaminase kidney isoform,
mitochondrial
Glutathione S-transferase kappa 1
Glutathione S-transferase Mu 2
Histone H1.0
High mobility group protein B1
Heterogeneous nuclear
ribonucleoprotein R
Sarcoplasmic reticulum histidinerich calcium-binding protein
3-hydroxyacyl-CoA dehydrogenase
type-2

Q9Y696

4.169

2.40

Q9H078
P30085
Q9UHQ9
P14868

0.458
6.667
0.526
0.340

0.14
2.32
0.07
0.06

H0Y368

0.096

0.06

Q13409
P30084
P68104

2.562
7.039
0.624

0.48
2.18
0.11

P68104

0.624

0.11

I3L504

12.005

4.01

I3L504

12.005

4.01

P30040
P00488
Q8NCA5

32.987
0.078
31.981

12.08
0.04
7.90

Q9Y613

4.336

1.45

Q00688

25.973

11.24

P02751

14.001

5.37

Q9H4G4

0.266

0.14

O94925
Q9Y2Q3
P28161
P07305
P09429

0.236
3.789
12.256
14.269
15.483

0.08
0.76
3.23
6.09
7.99

O43390

6.550

1.27

P23327

3.003

0.62

Q99714

0.368

0.04
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HSPA2
HSPB2
IDH3G
IKBIP
ILK
ITGA7
JPH1
JSRP1
KIAA009
0
LMO7
MAGT1
MAP4
MAPT
MCU
MTATP6
MTCO3
MVP
MYH1
NACA
NAP1L4
NEB
NIPSNAP
1
NME1
NME1NME2
NME2
PA2G4
PADI2
PBXIP1
PDIA4
PDLIM5

Heat shock-related 70 kDa protein
2
Heat shock protein beta-2
Isocitrate dehydrogenase [NAD]
subunit gamma, mitochondrial
Inhibitor of nuclear factor kappa-B
kinase-interacting protein
Integrin-linked protein kinase
Integrin alpha-7
Junctophilin-1
Junctional sarcoplasmic reticulum
protein 1

P54652
Q16082

4.584
5.175

1.10
1.85

P51553

0.191

0.09

Q70UQ0
Q13418
Q13683
Q9HDC5

6.037
0.449
0.133
8.611

1.52
0.16
0.07
3.08

Q96MG2

8.481

2.41

Uncharacterized protein KIAA0090
LIM domain only protein 7
Magnesium transporter protein 1
Microtubule-associated protein 4
Microtubule-associated protein tau
Calcium uniporter protein,
mitochondrial
ATP synthase subunit a
Cytochrome c oxidase subunit 3
Major vault protein
Myosin-1
Nascent polypeptide-associated
complex subunit alpha
Nucleosome assembly protein 1like 4
Nebulin

Q8N766
Q8WWI1
Q9H0U3
E7EVA0
P10636

34.524
0.084
0.127
3.428
6.510

11.84
0.04
0.09
0.79
1.84

Q8NE86
P00846
P00414
Q14764
P12882

2.658
0.294
0.253
5.133
0.209

0.53
0.03
0.05
1.86
0.05

E9PAV3

4.244

1.42

Q99733
P20929

127.136
4.166

48.51
1.18

Protein NipSnap homolog 1
Nucleoside diphosphate kinase A

Q9BPW8
Q32Q12

6.864
31.955

2.69
13.12

NME1-NME2 readthrough
Nucleoside diphosphate kinase B
Proliferation-associated protein
2G4
Protein-arginine deiminase type-2
Pre-B-cell leukemia transcription
factor-interacting protein 1
Protein disulfide-isomerase A4
PDZ and LIM domain protein 5

J3KPD9
P22392

31.955
31.955

13.12
13.12

Q9UQ80
Q9Y2J8

2.757
0.646

0.44
0.09

Q96AQ6
P13667
Q96HC4

2.025
2.524
3.139

0.43
0.44
0.56
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PGD
PLOD1
POR
PRKAB2
PRKAR2A
PSMA1
PSMC3
PSMD11
PSMD14
PSMD2
PSMD7
RCN3
RPL13A
RPL15
RPL17
RPL29
RPL30
RPL5
RPS12
RPS5
RPS6
SCCPDH
SEC11A
SEC23A
SEPT2
SEPT7
SFXN3
SLC12A2
SLC12A4
SLC25A1
3

6-phosphogluconate
dehydrogenase, decarboxylating
Procollagen-lysine,2-oxoglutarate
5-dioxygenase 1
NADPH--cytochrome P450
reductase
5-AMP-activated protein kinase
subunit beta-2
cAMP-dependent protein kinase
type II-alpha regulatory subunit
Proteasome subunit alpha type-1
26S protease regulatory subunit 6A
26S proteasome non-ATPase
regulatory subunit 11
26S proteasome non-ATPase
regulatory subunit 14
26S proteasome non-ATPase
regulatory subunit 2
26S proteasome non-ATPase
regulatory subunit 7
Reticulocalbin-3
60S ribosomal protein L13a
60S ribosomal protein
L15;Ribosomal protein L15
60S ribosomal protein L17
60S ribosomal protein L29
60S ribosomal protein L30
60S ribosomal protein L5
40S ribosomal protein S12
40S ribosomal protein S5
40S ribosomal protein S6
Saccharopine dehydrogenase-like
oxidoreductase
Signal peptidase complex catalytic
subunit SEC11A
Protein transport protein Sec23A
Septin-2
Septin-7
Sideroflexin-3
Solute carrier family 12 member 2
Solute carrier family 12 member 4
Calcium-binding mitochondrial
carrier protein Aralar2

P52209

4.370

1.58

B4DR87

0.490

0.04

P16435

0.359

0.15

O43741

2.629

0.60

P13861
P25786
P17980

3.597
53.646
3.605

0.88
20.64
1.14

O00231

5.877

2.23

O00487

6.075

2.15

Q13200

0.102

0.04

P51665
Q96D15
P40429

17.159
4.576
0.243

6.72
1.50
0.07

P61313
P18621
P47914
P62888
P46777
P25398
P46782
P62753

0.285
10.436
5.407
13.398
24.588
8.209
28.112
9.061

0.09
4.14
1.94
5.41
9.30
3.33
10.70
3.42

Q8NBX0

0.446

0.15

H0YK83
Q15436
Q15019
Q16181
Q9BWM7
P55011
Q9UP95

0.267
26.210
15.183
6.056
0.263
0.088
0.299

0.09
6.03
6.14
2.12
0.08
0.04
0.10

Q9UJS0

0.076

0.04
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SLC25A5
SPCS2
SQRDL
ST13
ST13P4
ST13P5
STOML2

STT3A

SUCLG1
SYNCRIP
TCP1
TMOD3
TNNT3
TOR1A
TP53RK
TPT1
TRAP1
TRIM72
UBA1
UGGT1
VAPB
VDAC2
VIM
XIRP1
YES1
ZYX

ADP/ATP translocase 2
Signal peptidase complex subunit 2
Sulfide:quinone oxidoreductase,
mitochondrial
Hsc70-interacting protein
Putative protein FAM10A4
Putative protein FAM10A5
Stomatin-like protein 2
Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit
STT3A
Succinyl-CoA ligase [ADP/GDPforming] subunit alpha,
mitochondrial
Heterogeneous nuclear
ribonucleoprotein Q
T-complex protein 1 subunit alpha
Tropomodulin-3
Troponin T, fast skeletal muscle
Torsin-1A
TP53-regulating kinase
Translationally-controlled tumor
protein
Heat shock protein 75 kDa,
mitochondrial
Tripartite motif-containing protein
72
Ubiquitin-like modifier-activating
enzyme 1
UDP-glucose:glycoprotein
glucosyltransferase 1
Vesicle-associated membrane
protein-associated protein B/C
Voltage-dependent anion-selective
channel protein 2
Vimentin
Xin actin-binding repeat-containing
protein 1
Tyrosine-protein kinase Yes
Zyxin

P05141
E9PI68

0.142
0.204

0.07
0.13

Q9Y6N5
P50502
P50502
P50502
Q9UJZ1

3.341
110.492
110.492
110.492
3.462

0.72
43.80
43.80
43.80
1.03

P46977

0.211

0.07

P53597

0.243

0.07

O60506
P17987
Q9NYL9
P45378
O14656
Q96S44

1.731
0.026
0.024
5.713
0.205
0.374

0.25
0.00
0.01
1.74
0.08
0.10

Q5W0H4

33.050

13.45

Q12931

0.639

0.09

Q6ZMU5

5.590

1.93

P22314

1.836

0.32

Q9NYU2

0.106

0.06

O95292

4.675

1.45

P45880
P08670

0.604
0.132

0.08
0.04

Q702N8
J3QRU1
Q15942

0.165
0.268
6.145

0.02
0.09
1.96
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CHARTER 6. FUTURE WORK
Protein kinases and their interaction partners have been extensively studied
due to the importance that kinases catalyze phosphorylation, which is one of the
most critical protein post-translational modifications that mediated numerous
molecular functions and biological processes. We successfully profiled the largest
functional kinome (54 protein kinases) and kinome interactome (616 proteins) in
human skeletal muscle using activity based enrichment probe and quantitative
proteomics. The future work of this project would be validate the significantly
changed protein kinases and their interaction partners by immunoblotting (i.e.,
western blots). Multiple protein identification and quantification techniques would
robust the results and draw much stronger conclusions. In addition, comparing
kinome and kinome interactome in type 2 diabetic patients to those in lean control
and obese insulin resistant participants will offers insights into type 2 diabetes
specific mechanisms.
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ABSTRACT
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Protein kinases play fundamental roles in regulation of biological processes
and functions, such as insulin signaling and glucose metabolism. Dysregulation of
protein kinases may cause impaired cell signaling and human diseases, such as
metabolic syndrome and type 2 diabetes (T2D). Skeletal muscle is the main site
responsible for insulin-stimulated glucose disposal, and insulin resistance in
skeletal muscle is one of the key features of the pathogenesis of T2D. Therefore,
malfunction of protein kinases and their interaction proteins may contribute to the
molecular mechanism of insulin resistance in human skeletal muscle. However, no
large scale profiling study has been reported to investigate the abnormal active
kinases and their interaction partners that might cause skeletal muscle insulin
resistance. Here, we present a high throughput platform coupling activity-based
ATP probes and quantitative proteomics to globally profile functional kinome and
its interactome in human skeletal muscle in 8 lean healthy and 8 obese insulin

199

resistant participants. We identified 54 active protein kinases in human skeletal
muscle, which is the largest catalog of experimental determined active kinases to
date. Twenty-two out of the 54 active kinases displayed a significant change in
insulin resistant obese subjects, including the protein kinases regulate JNK
signaling, p38 MAPK signaling, Wnt signaling, AMPK signaling, ERK1/2 signaling
and mTOR signaling. In addition, we identified 616 functional kinome interaction
partners in human skeletal muscle, which is the largest human kinome interactome
to date. Among the 616 interaction partners, 385 has a fold change > 1.5 or <0.67.
Out of these 385 kinome interaction partners, 135 displayed significantly difference
between lean heathy and insulin resistant obese subjects. The kinome interactome
participate in various cell signaling pathways (i.e. diabetes pathway, mTOR
pathway, insulin signaling pathway, etc.) and biofunctions (i.e. protein synthesis
and degradation, cytoskeleton dynamics, and apoptosis). In summary, we
generated the 1st global picture of functional kinome and kinome interactome in
skeletal muscle in lean heathy individuals, and how it differs in obese insulin
resistant participants. These results provide novel insights into molecular
mechanism of skeletal muscle insulin resistance, and may facilitate identifying new
targets for treating metabolic diseases.
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